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REGULATING CONFLICTS OF INTEREST IN RESEARCH:
THE PAPER TIGER NEEDS REAL TEETH

JESSE A. GOLDNER*

INTRODUCTION
[T]ell doctors that they have a “conflict of interest” in relation to a proposed
protocol for research with human subjects, and they believe that you have
accused them of unethical behavior. . . . [D]octors tend to assume that a
conflict of interest exists only when they actually have made a “bad” decision
motivated by their financial interest in the sponsor of their research.
Lawyers . . . view conflicts as objective, structural, and rule–based. You could
be a paragon of virtue, and you would be conflicted out of representing a client
if a prohibited conflict of interest exists. Doctors, in contrast, view conflicts of
interest as relating to the individual’s character and ability to resist temptation.
We lawyers might say that doctors just don’t get it when . . . we get defensive
1
at their response and fail to understand their starting point.

The scope of conflicts of interest in research is broad and dynamic. As
suggested in this introductory quote from an article by Sandra Johnson, the
2008 Richard J. Childress Memorial Lecture Keynote Speaker,2 there is a
fundamental disconnect between how conflicts of interest are viewed in law
versus medicine.3 Further, within the medical community itself, clinical
researchers approach, perceive, and respond to conflicts of interest quite
* John D. Valentine Professor of Law, Saint Louis University School of Law, Professor of Law
in Psychiatry and Professor of Pediatrics, Saint Louis University School of Medicine. The
research and editorial assistance of Elizabeth Gluck (Saint Louis University, J.D. 2009) and the
research assistance of Erin Brooks (J.D. Candidate, Saint Louis University, Class of 2010) is
gratefully acknowledged.
1. Sandra H. Johnson, Five Easy Pieces: Motifs of Health Law, 14 HEALTH MATRIX 131,
131–32 (2004) (footnote omitted).
2. This year’s Richard J. Childress Memorial Lecture, coinciding with Professor Johnson’s
retirement from teaching, honored her esteemed career as a teacher and scholar. See Symposium,
Saint Louis University School of Law Richard J. Childress Memorial Lecture: Still Crazy After
All These Years: Is Regulating Physician Practice an Exercise in Futility? (Oct. 17, 2008), in
Sandra H. Johnson, Regulating Physician Behavior: Taking Doctors’ “Bad Law” Claims
Seriously, 53 ST. LOUIS U. L.J. 973 (2009).
3. Johnson, supra note 1, at 131; Michelle M. Mello & Troyen A. Brennan, Demystifying
the Law/Science Disconnect, 26 J. HEALTH, POL. POL’Y & L. 429, 429 (2001).
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differently. No doubt, the vast majority of researchers comply with whatever
institutional or federal regulatory requirements apply to them. For many, the
rationales are obvious: regulatory requirements both protect the integrity of the
research process and help ensure public support of the research enterprise. For
others, perhaps at times they comply reluctantly—because regulatory
requirements are perceived as simply one more time-consuming effort in a
large series of bureaucratic steps that seemingly must be followed to enable
researchers to pursue their research. But when violations come to light at least
publicly, the typical consequence for both the investigator (and sometimes to
the institution) seems to be little more than embarrassment. One could readily
describe the current regulatory regime as simply a paper tiger. In the absence
of truly significant government regulation of these conflicts in research, the
varied approaches pose unique challenges for institutions that support such
research.4
This article will address the current state of conflicts of interest in research.
Following a discussion in Section I of how the academic research environment
has changed over the past twenty-five years, Section II will consider recent
empirical research on such conflicts. The data suggests, contrary to beliefs
held by many clinicians and researchers, that conflicts of interest can and often
do, at least unconsciously, affect how they behave and the outcomes of their
studies. Section II will also review additional recent empirical analyses,
directed to the question of how potential research subjects view disclosure of
conflicts of interest. Section III will touch on a number of widely publicized
research “scandals” involving conflicts of interest that likely have had a
negative effect on public support for the research enterprise, but also may well
result in the delivery of lower quality of care when clinicians reject otherwise
good science out of concern for the apparent conflicts of interest in published
research.
Section IV will discuss current federal regulations and initiatives by
institutions and professional organizations to further guide researchers. The
nature of the historical resistance to placing any significant limitations on
conflicts of interest stems from a wide variety of attitudes by researchers that
affect their behavior. Such attitudes can be grouped into general categories,
and Section V presents a “Taxonomy of Researchers,” based primarily on my
own membership on a university conflict of interest committee over a four year
period.
Section VI will discuss how, once identified, conflicts of interest are
typically managed by institutions, and critiques by the Office of the Inspector
General of the Department of Health and Human Services (OIG) of the federal
4. “Research,” as it is used in this article, means “a systematic investigation, including
research development, testing, and evaluation, designed to develop or contribute to generalizable
knowledge.” 45 C.F.R. § 46.102(d) (2008).
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government’s role in the current interplay between government agencies,
sponsors, and institutions in regulating conflicts. Collectively, Sections I
through VI will demonstrate that the existing world of conflict of interest
regulations is shamefully inadequate. Section VII will, therefore, set forth a
proposal for reform of the way conflicts of interest are managed at both the
federal and institutional levels. As Section VII will argue, the conflict of
interest picture is not entirely bleak, and the adoption of a critically necessary
uniform set of governmental regulations could help minimize the likelihood of
further scandals and help restore public confidence in research.
This article will not address non-financial conflicts presented by
researchers’ efforts to climb the academic ladder.5 While real, these conflicts,
arguably, are unavoidable given the nature of the academic enterprise. Also
beyond the scope of this article are institutional conflicts of interest6 and
conflicts of interest that may be presented by membership on an Institutional
Review Board (IRB).7
I. CHANGES IN THE RESEARCH ENVIRONMENT AND THE EFFECTS ON
CONFLICTS OF INTEREST
Universities, prior to the 1970s, and through the 1980s, were governed to a
significant extent by what can be termed the “collegial ethos.” The institutions
were perceived as having a public interest mission, whether they were public
or private not-for-profits.8 The relationship between the university and
external institutions generally emphasized the former’s financial independence
from the latter.9 Another aspect, internal relationships, also emphasized

5. See Norman G. Levinsky, Nonfinancial Conflicts of Interest in Research, 347 NEW ENG.
J. MED. 759, 759 (2002).
6. See Eric G. Campbell et al., Institutional Academic-Industry Relationships, 298 JAMA
1779 (2007); Michael M.E. Johns et al., Restoring Balance to Industry-Academia Relationships in
an Era of Institutional Financial Conflicts of Interest, 289 JAMA 741, 741 (2003); Hamilton
Moses III et al., Collaborating with Industry—Choices for the Academic Medical Center, 347
NEW. ENG. J. MED 1371, 1371 (2002); see also Nicholas H. Steneck, Institutional and Individual
Responsibilities for Integrity in Research, 2 AM. J. BIOETHICS 51 (2002).
7. See Eric G. Campbell et al., Financial Relationships Between Institutional Review Board
Members and Industry, 355 NEW. ENG. J. MED. 2321, 2321 (2006).
8. See AM. ASS’N OF UNIV. PROFESSORS, 1940 STATEMENT OF PRINCIPLES ON ACADEMIC
FREEDOM AND TENURE 3 (2006) [hereinafter AAUP, 1940 STATEMENT], available at
http://www.aaup.org/NR/rdonlyres/EBB1B330-33D3-4A51-B534-CEE0C7A90DAB/0/1940State
mentofPrinciplesonAcademicFreedomandTenure.pdf (“Institutions of higher education are
conducted for the common good and not to further the interest of either the individual teacher or
the institution as a whole. The common good depends upon the free search for truth and its free
exposition.” (footnote omitted)). For-profit institutions of higher education rarely have the
conduct of research as part of their mission. See RICHARD S. RUCH, HIGHER ED, INC.: THE RISE
OF THE FOR-PROFIT UNIVERSITY (2003).
9. See AAUP, 1940 STATEMENT, supra note 8.
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independence, focusing on the central role of faculty rights to academic
freedom that provide faculty with the autonomy and independence to define
and control their work.10 That academic freedom is essential to enable faculty
to work in a way that fulfills the university’s public mission and its social role
as a public trust, free from the influence of third parties such as university
administrators, the government, or commercial enterprises.11 The government,
to a large extent, and perhaps only until more recently, has trusted the
universities to do the right thing and to govern themselves because, after all,
the Ivory Tower was just that—relatively unaffected by the capitalist ethos of
pursuing profit, especially in a particularly aggressive manner.12
Beyond ordinary salary support for research, there was little, perhaps other
than tenure, promotion, and increased collegial recognition, which individuals
could obtain through their research efforts within the university. Prior to the
1980s, little public attention was paid to pharmaceutical and device
manufacturers and other corporate entities that offered the kinds of valuable
financial incentives to engage in collaborative efforts with faculty members
that they currently offer.13 This is likely because, relatively speaking, little
such behavior was occurring. The perception was that university researchers
were people who had chosen to forgo greater financial rewards in the public
sector for the noble, bucolic, but relatively poverty-stricken, academic
environment. The external public had little interest in the financial aspects of
the “research environment.”
The minimal focus on the research enterprise that existed dealt largely with
the treatment of research subjects, courtesy of the Nazi experiments,14 Henry

10. Risa L. Lieberwitz, Confronting the Privatization and Commercialization of Academic
Research: An Analysis of Social Implications at the Local, National, and Global Levels, 12 IND.
J. GLOBAL LEGAL STUD. 109, 109–10 (2005).
11. Id. at 109–10, 114–15.
12. Id. at 113, 115–16; see DEREK BOK, UNIVERSITIES IN THE MARKETPLACE: THE
COMMERCIALIZATION OF HIGHER EDUCATION 185–98 (2003); LAWRENCE C. SOLEY, LEASING
THE IVORY TOWER: THE CORPORATE TAKEOVER OF ACADEMIA 5–15 (1995); JENNIFER
WASHBURN, UNIVERSITY INC.: THE CORPORATE CORRUPTION OF AMERICAN HIGHER
EDUCATION 103–36 (2005).
13. See Dana Katz et al., All Gifts Large and Small: Toward an Understanding of the Ethics
of Pharmaceutical Industry Gift-Giving, 3 AM. J. BIOETHICS 39, 39 (2003); see also, S.
Madhavan et al, The Gift Relationship Between Pharmaceutical Companies and Physicians: An
Exploratory Survey of Physicians, 22 J. CLINICAL PHARMACY & THERAPEUTICS 207, 211–13
(1997).
14. See generally ROBERT JAY LIFTON, THE NAZI DOCTORS: MEDICAL KILLING AND THE
PSYCHOLOGY OF GENOCIDE (1986); THE NAZI DOCTORS AND THE NUREMBERG CODE: HUMAN
RIGHTS IN HUMAN EXPERIMENTATION (George J. Annas & Michael A. Grodin eds., 1992)
(suggesting that the trial of Nazi physicians in post-World War II Nuremberg, Germany can be
used as a basis from which to question the permissible limits of human experimentation and the
focus on universal ethical codes within the context of the criminal trial).
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Beecher’s article in the New England Journal of Medicine chronicling
previously unidentified unethical activities by researchers in the United
States,15 and the Tuskegee Syphilis Study.16 Congressional hearings on these
concerns led to the passage of the National Research Act of 1974.17
The Act created the National Commission for the Protection of Human
Subjects of Biomedical and Behavioral Research18 that issued the Belmont
Report,19 which set forth ethical principles for the conduct of human research.
The Act also called for the issuance of federal regulations establishing certain
requirements for institutions conducting such research.20 Among these
requirements was a mandate that institutions receiving federal funds enter into
assurances with the federal government that research be conducted in an
ethical manner. They also required that the institutions develop IRBs that
would conduct a risk-benefit analysis of a research proposal and review both
the proposed content of the information provided to obtain potential subjects in
an effort to obtain informed consent and the method of doing so.21 But there
was preciously little in the Belmont Report that even alluded to potential
conflicts of interest, nor is there a single word about conflicts of interest in the
federal IRB regulations, which have remained largely unchanged in the human
subjects research context since the late 1970s.22

15. Henry K. Beecher, Ethics and Clinical Research, 274 NEW ENG. J. MED. 1354, 1354
(1966).
16. See JAMES H. JONES, BAD BLOOD: THE TUSKEGEE SYPHILIS EXPERIMENT, at ix (New &
Expanded ed. 1993).
17. National Research Service Award Act of 1974, Pub. L. No. 93–348, 88 Stat. 342
(codified as amended in scattered sections of 42 U.S.C. (2006)); see generally Jesse A. Goldner,
An Overview of Legal Controls on Human Experimentation and the Regulatory Implications of
Taking Professor Katz Seriously, 38 ST. LOUIS U. L.J. 63 (1993). For a history of the events that
led up to the development of regulations on the conduct of research with human subjects, see
COLEMAN ET AL., THE ETHICS AND REGULATION OF RESEARCH WITH HUMAN SUBJECTS
§§ 1.03–2.01, at 16–61 (2005).
18. National Research Service Award Act of 1974 § 201; see COLEMAN ET AL, supra note
17, § 2.01, at 52.
19. COLEMAN ET AL., supra note 17, § 2.01, at 52; NAT’L COMM’N FOR THE PROTECTION
OF HUMAN SUBJECTS OF BIOMEDICAL & BEHAVIORAL RESEARCH, THE BELMONT REPORT:
ETHICAL PRINCIPLES AND GUIDELINES FOR THE PROTECTION OF HUMAN SUBJECTS OF
RESEARCH (1979) [hereinafter BELMONT REPORT], available at http://ohsr.od.nih.gov/guidelines/
belmont.html.
20. National Research Service Award Act of 1974, §§ 211–12.
21. Id. § 212.
22. 45 C.F.R. § 46.101–.409 (2008); see, e.g., Carol Mason Spicer, Federal Oversight and
Regulation of Human Subjects Research—An Update, 10 KENNEDY INST. ETHICS J. 261, 263
(2000) (noting various statements released by the Department of Health and Human Services
(HHS), including the need for additional guidance regarding conflicts of interest in research
involving human subjects); see generally COLEMAN ET AL., supra note 17, § 2.01, at 51–61
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At best, and only by inference, the issue of conflicts of interest might
conceivably come into play in two ways. First, in an IRB’s analysis of risk,23
it may find that there is the attenuated possibility that a financial conflict of
interest might lead an investigator to (a) cheat on inclusion and exclusion
criteria when recruiting subjects, (b) inappropriately keep subjects on a
protocol in order to complete the study, or (c) falsify data in an effort to make a
test article24 appear safer and more efficacious than the actual facts would
suggest. A second, again inferential and related reference to conflicts of
interest, might be seen in the section of the federal regulations that details the
elements of informed consent that requires a description of “any reasonably
foreseeable risks.”25
The university academic environment has changed radically, yet there is no
one cause to which this change can be attributed. Far more research,
percentage-wise, is supported by private sources than by the federal
government.26 As of 2003, academic health centers performed nearly thirty

(providing an overview of governmental oversight of research with human subjects from the
1960s to 1990s).
23. See 45 C.F.R. § 46.111(a)(1)–(2); accord 21 C.F.R. § 56.111(a)(1)–(2) (2008).
24. A “test article” is any drug, biological product, or medical device for human use. 21
C.F.R § 56.102(1).
25. See 45 C.F.R. § 46.116(a)(2); accord 21 C.F.R. § 50.25(a)(2).
26. Although the federal government has been the primary source of funding for clinical
research in the past, it has been superseded by private industry in the last decade. There is
a pronounced trend toward a greater percentage of research being funded by the private
sector. One study has shown that 28% of life sciences faculty received private sponsor
funding. In 1986, the private sector funded 42% of health care research and development.
By 1995, the private sector’s allocation of research dollars had risen to 52%. This equated
to a three-fold increase, from approximately $6 billion to $19 billion. Thus, although
federal funding of research has incrementally increased over time, the private funding has
increased exponentially.
Patricia C. Kuszler, Curing Conflicts of Interest in Clinical Research: Impossible Dreams and
Harsh Realities, 8 WIDENER L. SYMP. J. 115, 118–19 (2001) (footnotes omitted).
Biomedical research funding increased from $37.1 billion in 1994 to $94.3 billion in 2003
and doubled when adjusted for inflation. Principal research sponsors in 2003 were
industry (57%) and the National Institutes of Health (28%). Relative proportions from all
public and private sources did not change. Industry sponsorship of clinical trials
increased from $4.0 to $14.2 billion (in real terms) while federal proportions devoted to
basic and applied research were unchanged. The United States spent an estimated 5.6% of
its total health expenditures on biomedical research, more than any other country, but less
than 0.1% for health services research. From an economic perspective, biotechnology and
medical device companies were most productive, as measured by new diagnostic and
therapeutic devices per dollar of research and development cost. Productivity declined for
new pharmaceuticals.
Hamilton Moses III et al., Financial Anatomy of Biomedical Research, 294 JAMA 1333, 1333
(2005); see also David Blumenthal et al., University-Industry Research Relationships in
Biotechnology: Implications for the University, 232 SCIENCE 1361, 1364 (1986).
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percent of all the health care research and development in the United States
and more than fifty percent of research supported by the National Institutes of
Health (NIH).27 Nonetheless, there has been a significant shift in research
from academic centers to private hospitals and physicians in private practice.28
Increasing costs of bringing drugs and devices to market29 have led industry to
look elsewhere in an effort to avoid the bureaucracy endemic to universities,
and move research sites to private physicians and to for-profit contract research
organizations and other independent research enterprises.30 The Bayh-Dole
Act, passed in 1980, encourages academic institutions, supported by federal
grants, to patent and license new products developed by their faculty members
and to share royalties with the researchers.31 In many respects this legislation,
though designed to facilitate the transfer of technology from academic
institutions to bedside, has had the unintended consequence of blurring
distinctions between academic entities and researchers on the one hand and
commercial entities on the other.
Even while seeking non-academic research environments to conduct
research, industry recognizes that academic clinicians remain the “thought
leaders”32 and are very willing to handsomely reward such individuals for
giving continuing medical education talks that are likely to increase the sales
of new products, or for putting their names on academic papers to which they
may contribute little, if anything, substantively. The point to be made is that
now there is money to be had—sometimes in such significant amounts as to
dwarf an academic salary. In 1985, 2.6% of principal investigators had
personal financial ties to their industry sponsors, but by 1999, that figure had
been raised to 7.6%.33 No doubt this figure has grown exponentially in the
interim. In 2007, 60% of departmental chairs in academic medical centers had
some form of personal relationship with industry.34

27. THE COMMONWEALTH FUND TASK FORCE ON ACADEMIC HEALTH CTRS., ENVISIONING
FUTURE OF ACADEMIC HEALTH CENTERS 3, 31 (2003), available at http://www.common
wealthfund.org/usr_doc/ahc_envisioningfuture_600.pdf?section=4039.
28. See generally Thomas Bodenheimer, Uneasy Alliance—Clinical Investigators and the
Pharmaceutical Industry, 342 NEW ENG. J. MED. 1539, 1539 (2000).
29. Id. at 1540.
30. COLEMAN ET AL., supra note 17, § 2.03, at 77–86; see, e.g., Covance: The CRO for
Drug Development Services, http://www.covance.com/ (last visited July, 30 2009); INC
Research, http://www.incresearch.com (last visited July 30, 2009); MDS Pharma Services,
http://www.mdsps.com (last visited July 30, 2009), Pharmaceutical Product Development,
http://www.ppdi.com (last visited July 30, 2009).
31. 35 U.S.C. §§ 200–212 (2006); see also 37 C.F.R. § 401 (2008) (implementing the Act).
32. See Nikolaos A. Patsopoulos et al., Origin and Funding of the Most Frequently Cited
Papers in Medicine: Database Analysis, 332 BRIT. MED. J. 1061, 1061–63 (2006).
33. Elizabeth A. Boyd & Lisa A. Bero, Assessing Faculty Financial Relationships with
Industry: A Case Study, 284 JAMA 2209, 2211 (2000).
34. Campbell et al., supra note 6, at 1783.
THE
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II. EMPIRICAL STUDIES OF THE IMPLICATIONS OF CONFLICTS OF INTEREST
A.

Definition and Types of Conflicts

There are numerous definitions of conflicts of interest. For the purposes of
this article, a conflict of interest is defined as a “set of conditions in which
professional judgment . . . (such as a patient’s welfare or the validity of
research) tends to be unduly influenced by a secondary interest (such as
financial gain).”35 Examples in the research area include, but are not limited
to: (1) various forms of payments to investigators in connection with the
recruitment of subjects, such as per capita payments to investigators for
recruiting subjects; (2) various forms of bonus payments for boosting subject
enrollment or meeting enrollment deadlines; (3) finder’s fees to those who
refer subjects to investigators; (4) gifts from industry sponsors, including
discretionary funds, research equipment, and support for travel to professional
meetings (often in exotic locales that more closely resemble vacations); (5)
stock ownership; (6) highly paid consultant positions; and (7) excessive
compensation for providing continuing medical education lectures.36
B.

Empirical Research on Clinician Behavior and Study Outcomes

Until recently there was a relative paucity of empirical research on
conflicts of interest and clinician behavior. Today, a number of scholars are
devoting significant efforts to examining issues such as physician behaviors in
response to sponsor offers of various inducements;37 the failure of journals to
adhere to their own guidelines regarding the publication of research and

35. Justin E. Bekelman et al., Scope and Impact of Financial Conflicts of Interest in
Biomedical Research: A Systematic Review, 289 JAMA 454, 454 (2003) (quoting Dennis F.
Thompson, Understanding Financial Conflicts of Interest, 329 NEW ENG. J. MED. 573, 573
(1993)).
36. Jesse A. Goldner, Dealing with Conflicts of Interest in Biomedical Research: IRB
Oversight as the Next Best Solution to the Abolitionist Approach, 28 J.L. MED. & ETHICS 379,
381–84 (2000); see Neal Dickert et al., Paying Research Subjects: An Analysis of Current
Policies, 136 ANNALS INTERNAL MED. 368 (2002); Neal Dickert & Christine Grady, What’s the
Price of a Research Subject? Approaches to Payment for Research Participation, 341 NEW ENG.
J. MED. 198 (1999); Trudo Lemmens & Paul B. Miller, The Human Subjects Trade: Ethical and
Legal Issues Surrounding Recruitment Incentives, 31 J.L. MED. & ETHICS 398 (2003); see
generally COLEMAN ET AL., supra note 17, § 5.02, at 235–37.
37. Jason Dana & George Loewenstein, A Social Science Perspective on Gifts to Physicians
from Industry, 290 JAMA 252 (2003); Madhavan et al., supra note 13; Bruce M. Psaty &
Drummond Rennie, Clinical Trial Investigators and Their Prescribing Patterns: Another
Dimension to the Relationship Between Physician Investigators and the Pharmaceutical Industry,
295 JAMA 2787 (2006); David M. Studdert et al., Financial Conflicts of Interest in Physicians’
Relationships with the Pharmaceutical Industry—Self-Regulation in the Shadow of Federal
Prosecution, 351 NEW ENG. J. MED. 1891 (2004).
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conflicts of interest;38 relationships between financial conflicts of interest and
voting patterns at Food and Drug Administration (FDA) advisory committee
meetings;39 and relationships between individuals reporting conflicts of interest
and the likelihood that they would report positive results on the one hand,40
and the extremely small likelihood, on the other hand, that authors with
conflicts of interest would publish negative results.41
Data from empirical research examining conflicts of interest in clinical
medicine and research is not at all surprising, but rather, it is disheartening.
There is a statistically significant relationship between positive findings in
studies funded by for-profit entities versus those funded by not-for-profit
sources,42 between industry sponsorship and pro-industry conclusions,43 and
between author conflicts of interest and the greater likelihood of reporting a
drug to be superior to placebo.44 Industry funding may result in study designs
that are more likely to lead to favorable results, such as utilizing protocols that
involve placebos or other poor comparators, doses that are inappropriate,
carefully constituted experimental populations, inappropriate surrogate
endpoints, trials whose lengths are sufficiently short so as to be unlikely to
show side effects, and definitions that are unlikely to show activity or not
likely to show side effects.45 Industry sponsorship is also associated with

38. Joel Lexchin et al., Pharmaceutical Industry Sponsorship and Research Outcome and
Quality: Systemic Review, 326 BRIT. MED. J. 1167, 1167 (2003); Susan Mayor, Surgery Journal
Bans Authors Who Hide Conflicts of Interest, 332 BRIT. MED. J. 135, 135 (2006).
39. Peter Lurie et al., Financial Conflict of Interest Disclosure and Voting Patterns at Food
and Drug Administration Drug Advisory Committee Meetings, 295 JAMA 1921, 1921 (2006).
40. Bekelman, supra note 35; Mohit Bhandari et al., Association Between Industry Funding
and Statistically Significant Pro-Industry Findings in Medical and Surgical Randomized Trials,
170 CAN. MED. ASS’N J. 477, 477 (2004); Lee S. Friedman & Elihu D. Richter, Relationship
Between Conflicts of Interest and Research Results, 19 J. GENERAL INTERNAL MED. 51 (2004);
Robert E. Kelly, Jr. et al., Relationship Between Drug Company Funding and Outcomes of
Clinical Psychiatric Research, 36 PSYCHOL. MED. 1647 (2006); Lexchin et al., supra note 38;
Patsopoulos et al., supra note 32, at 1061; Roy H. Perlis et al., Industry Sponsorship and
Financial Conflict of Interest in the Reporting of Clinical Trials in Psychiatry, 162 AM. J.
PSYCHIATRY 10 (2005); John Yaphe et al., The Association Between Funding by Commercial
Interests and Study Outcome in Randomized Controlled Drug Trials, 18 FAM. PRAC. 565, 565–68
(2001). But see Thomas P. Stossel, A Biopsy of Financial Conflicts of Interest in Medicine, 143
SURGERY 193, 196 (2008).
41. Friedman & Richter, supra note 40, at 53, 55.
42. Paul M. Ridker & Jose Torres, Reported Outcomes in Major Cardiovascular Clinical
Trials Funded by For-profit and Not-for-Profit Organizations, 295 JAMA 2270, 2272 (2006).
43. Bekelman et al., supra note 35, at 463; Bhandari et al., supra note 40, at 478–79;
Friedman & Richter, supra note 40, at 55; Kelly et al., supra note 40, at 1653; Lexchin et al.,
supra note 38, at 1169.
44. Perlis et al., supra note 40, at 19.
45. Sergio Sismondo, How Pharmaceutical Industry Funding Affects Trial Outcomes:
Causal Structures and Responses, 66 SOC. SCI. & MED 1909, 1910–12 (2008).
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restrictions on publication and data sharing.46 Such restrictions and the
selective reporting of more favorable pro-protocol analysis can result in
erroneous conclusions based on published data.47 On the purely clinical side,
for example, research has shown that a drug company’s hosting of an allexpense-paid trip to a resort for a seminar had substantial effects on the
attendee-physicians’ prescribing patterns.48 More generally, it has been shown
“that favors and promotional items of negligible value can influence behavior
of the recipient in ways the recipient does not often realize.”49 As Dr. Arthur
Caplan, director of the Center for Bioethics at the University of Pennsylvania’s
School of Medicine, has noted:
Even small gifts can influence behavior . . . .
The doctors who say, “I can’t be bought for a piece of pizza or a free box of
doughnuts,” aren’t paying attention to what empirical science shows influences
people . . . . It isn’t just a drug company giving out $25,000 to give a talk and
go on a nice vacation—that would certainly influence you. But even if (a drug
rep) shows up with a free lunch every week for 50 weeks, it tends to build a
50
sense of reciprocity on the part of the people who get the free gift.

C. Empirical Studies of the Effects of Disclosures of Conflicts of Interest on
Research Participants
Another area of empirical research related to conflicts of interest in the
research enterprise has been the reactions and perceptions of research subjects
to disclosures regarding conflicts of interest. For the most part, these studies
have demonstrated little concern on the part of participants with the nature of
the disclosures made.
Thus, for example, in one study patients with diabetes or asthma were read
descriptions of a hypothetical clinical trial with one of five financial disclosure

46. Bekelman, et al., supra note 35, at 454; Jerome M. Stern & R. John Simes, Publication
Bias: Evidence of Delayed Publication in a Cohort Study of Clinical Research Projects, 315
BRIT. MED. J. 640, 644 (1997).
47. Frank Peinemann et al., Negative Pressure Wound Therapy: Potential Publication Bias
Caused by Lack of Access to Unpublished Study Results Data, 8 BMC MED. RESEARCH METHOD.
4, 4 (2008), http://www.biomedcentral.com/1471-2288/8/4.
48. James P. Orlowski & Leon Wateska, The Effects of Pharmaceutical Firm Enticements
on Physician Prescribing Patterns: There’s No Such Thing as a Free Lunch, 102 CHEST 270,
270–71 (1992); see also Sarah Boseley & Rob Evans, Drug Giants Accused Over Doctors’ Perks,
THE GUARDIAN, Aug. 23, 2008, http://www.guardian.co.uk/society/2008/aug/23/health.pharma
ceuticals.
49. Katz et al., supra note 13, at 42; see also COLEMAN ET AL., supra note 17, § 2.02, at 61–
77.
50. Janet Moore, U Plan: Ban All Gifts to Doctors, MINN. STAR TRIB., Oct. 21, 2008, at 1A
(quoting Arthur Caplan, Dir., Ctr. for Bioethics at the Univ. Penn. Sch. of Med.) (internal
quotation marks omitted).
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statements: (1) a generic disclosure that the principal investigator might benefit
financially; (2) the principal investigator would receive per capita payments
from the sponsor to support salaries of research staff and supplies; (3) the study
is supported by the sponsor, and the principal investigator receives additional
money for consulting, giving speeches, or writing reports; (4) the principal
investigator has an investment in the sponsor’s stock and therefore could gain
or lose money depending on the results; and (5) the institution conducting the
study has an investment in the sponsor’s stock.51 The study results indicated
respondents were sensitive to some of the financial interest disclosed, and that,
in particular, they viewed ownership of equity interests less favorably than
receiving per capita payments ,52 with other financial conflicts falling between
these two extremes.53 Nonetheless, patients’ willingness to participate did not
substantially differ among other types of disclosure, as 45% to 59% were very
willing to participate.54 Other factors, such as potential benefits and risks and
the purposes of the research were deemed to be more important in making a
decision.55 Some respondents were surprised to learn about the equity interests
and expressed concern if they were not disclosed.56 Some 59% felt that the
possibility that the researcher or institute might benefit financially did not
change their trust in the researcher or institution.57 Over a third of the
respondents, however, were less trusting in the researchers and institutions as a
result of the disclosures.58 For some, of course, the disclosure might have
increased trust based on the potential participants’ perception of increased
honesty.59 In general, however, changes in trust did seem to be related to
variations in an individual’s willingness to participate in a study, but there was
a perception that financial interests lowered the scientific quality of the
hypothetical trial.60 Other similar studies showed that types of disclosures had
little or no influence.61
In another study, involving patients in cancer-research trials, nearly 90%
expressed little or no worry about financial ties of researchers or institutions,

51. Kevin P. Weinfurt et al., Effects of Disclosing Financial Interests on Attitudes Toward
Clinical Research, 23 J. GEN. INTERNAL MED. 860, 861 (2008).
52. Id.; accord Lindsay A. Hampson et al., Patients’ Views on Financial Conflicts of Interest
in Cancer Research Trials, 355 N.EW ENG. J. MED. 2330, 2336 (2006).
53. Weinfurt et al., supra note 51, at 862.
54. Id. at 864.
55. Id. at 862.
56. Id.
57. Id.
58. Weinfurt et al., supra note 51, at 862, 864.
59. Id. at 864.
60. Id. at 863–64.
61. Jeffrey N. Gibbs & Gregory A. Guagnano, Investigator Financial Disclosures and Its
Effect on Research Subjects, 62 FOOD & DRUG L.J. 727, 735 (2007).
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including researchers receiving speakers’ fees (82%), consulting fees (75%),
royalty payments (70%), and stock ownership (77%).62 Less than 15% of
patients indicated that knowledge of a financial tie would have kept them from
participating.63 Eighty-one percent believed it was ethical for a researcher
whose drug was being evaluated in the trial to receive speaking fees, and 82%
thought it was ethical to receive consulting fees.64 Seventeen percent of the
participants thought that no disclosure to patients was even necessary, while
some 40% said they wanted disclosure of the oversight system for the
researcher, and 31% believed that there should be a requirement to disclose all
financial ties.65
In one further study, using focus groups of potential research participants,
the individuals wanted to know about financial interests, irrespective of
whether or not those would affect their participation. 66 The study indicated
that potential research participants varied in both the desire and ability to
understand the nature and implications of information provided.67 It further
concluded that as a result of the group sessions, participants were better able to
identify information they would want to obtain.68
Finally, in what the authors, Christine Grady and her colleagues, indicated
was the first published qualitative study reporting research participants’ views
regarding financial interests of investigators,69 the study design involved a
face-to-face, semi-structured interview with patients with serious, lifethreatening, or chronic conditions.70 Most were long-term participants in
clinical studies.71
They were presented with a hypothetical clinical trial “in which the
principal investigator [either] . . . 1) held a patent on the intervention being
tested . . . , 2) held stock in the company that made the investigational
intervention, 3) received consulting fees from [that] company . . . , or 4)
received funding from the sponsoring company over and above per participant
costs of the study.”72

62. Hampson et al., supra note 52, at 2333, 2335 tbl.3.
63. Id. at 2333.
64. Id. at 2334, 2335 tbl.4.
65. Id. at 2336 tbl.5.
66. Kevin P. Weinfurt et al., Views of Potential Research Participants on Financial
Conflicts of Interest: Barriers and Opportunities for Effective Disclosure, 21 J. GEN. INTERNAL
MED. 901, 903–04 (2006).
67. Id. at 903–05.
68. Id. at 904.
69. Christine Grady et al., The Limits of Disclosure: What Research Subjects Want to Know
About Investigator Financial Interests, 34 J.L. MED. & ETHICS 592, 597 (2006).
70. Id. at 592–93.
71. Id. at 593.
72. Id.
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After reviewing the scenarios, almost all of the interviewees indicated that
they trusted the researchers and the research team and would recommend the
study to others.73 Responses to each of the scenarios ranged from “concerns
about data integrity and ‘conflicts of interest’” to an acceptance of the idea that
the principal investigator’s expertise and hard work deserved financial awards,
to indifference or ambivalence, recognizing the financial rewards’ legitimacy
“but worrying about money’s potential corrupting influence.”74
The more educated the individual, however, the more concern was
expressed about financial interests having a potential for manipulating or
fudging data.75 As was noted with the prior study described above, most
wanted to know both about the existence of an investigator’s financial
relationship and the fact that safeguards had been put in place by the institution
to monitor financial interests and protect data integrity.76 But, “[o]nly a few
wanted full disclosure, including” details regarding “the amount of money an
investigator might receive.”77 Most significantly, nearly two-thirds said that
receiving information such as that in the four scenarios would have no impact
on their decisions or willingness to participate, again, typically because other
factors were more important or because they trusted institutional safeguards
that they assumed were in place to oversee the financial conflicts.78 Some did
not want financial information “because it did not matter to them or was
perceived as a burden” they did not want to shoulder.79
“Several
acknowledged that concerns about the financial interests depended on the
severity of their clinical condition,” alternative treatment options, and “hope in
the possibility of benefit from a trial.”80 More serious illnesses and limited
options were associated with less concern about financial interest.81
It is not surprising that there are indications that potential research subjects
generally are not terribly troubled when they review consent documents
disclosing conflicts of interest information (perhaps other than ownership of
equity interests),82 in the sense that conflicts of interest are unlikely to cause
them to refuse to participate in a study. An ill individual often is unaware of
what scholars have identified as the “therapeutic misconception.”83 Nor do

73. Id. at 594.
74. Grady et al., supra note 69, at 594, 595 tbl.3.
75. Id. (internal quotation marks omitted).
76. Id. at 596; see supra text accompanying notes 62–65.
77. Grady et al., supra note 69, at 597–98.
78. Id.
79. Id. at 597.
80. Id.
81. Id.
82. See supra text accompanying notes 52–54.
83. See, e.g., Paul S. Appelbaum et al., False Hopes and Best Data: Consent to Research
and the Therapeutic Misconception, HASTINGS CENTER REP., Apr. 1987, at 20; Lisa M. Arkin et

GOLDNER_ARTICLE.DOC

1224

SAINT LOUIS UNIVERSITY LAW JOURNAL

[Vol. 53:1211

potential participants necessarily understand the related concept of “clinical
equipoise.”84
The therapeutic misconception is a fundamental confusion among research
subjects between the goals of clinical care (improving the health of an
individual patient) and the goals of research (generalizable knowledge).85
Despite clear information to the contrary that may appear in consent
documents, a patient frequently will believe that the project in which he or she
has consented to participate was designed to benefit the patient directly, and
not to contribute to generalizable knowledge.86 Of course, this simply is not
true. Patients, when asked why they agreed to be in a study, often will indicate
that “the medication [they] will receive, they believe[ ], will be the one most
likely to help [them].”87 The patient will, incorrectly, “rule[ ] out the
possibility that he might receive a placebo” as that “would not be likely to do
him much good,” thus denying that there may be major disadvantages to
participating in research.88 In so doing, the patient would also be denying the
possibility that the patient’s interest could well be “secondary to other demands
on the physician-researcher’s loyalties.”89
This confusion typically will occur because the patient may not adequately
comprehend the nature of clinical research. Such research generally involves
techniques of randomization and the use of control groups.90 Each of these
may result in the patient being placed on a placebo or perhaps on a drug that he
or she would have received by virtue of the then existing standard of care
without being on a protocol. This absolute belief that the individual will
receive the test article can be seen in comments made by respondents in some
of the studies discussed above.91

al., Confronting the Issues of Therapeutic Misconception, Enrollment Decisions, and Personal
Motives in Genetic Medicine-Based Clinical Research Studies for Fatal Disorders, 16 HUM.
GENE THERAPY 1028, 1029–30 (2005); Charles W. Lidz & Paul S. Appelbaum, The Therapeutic
Misconception: Problems and Solutions, 40 MED. CARE, at V-55, V-57 (2002); Franklin G.
Miller & Howard Brody, A Critique of Clinical Equipoise: Therapeutic Misconception in the
Ethics of Clinical Trials, HASTINGS CENTER REP., May–June 2003, at 19, 20.
84. See Miller & Brody, supra note 83.
85. Appelbaum et al., supra note 83, at 20; see also Lidz & Appelbaum, supra note 83, at V57.
86. See Appelbaum et al., supra note 83, at 20.
87. Id.
88. Id.
89. Id.
90. Id. at 20–21.
91. See, e.g., Grady, et al., supra note 69, at 593–94, 596–97 (noting that “[a]lmost all”
subjects in the study of participant attitudes toward disclosure “said they enrolled because the . . .
study offered what looked like the best treatment option for them;” that some did not want to be
informed because “[i]t is just too much. . . . I already know what I want. And I don’t want to read
anything or hear anything that’s going to deter me from getting what I came to NIH for;” that
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Under standard of care treatment, off-protocol, the patient might well not
have to deal with inconvenient or uncomfortable aspects of the study. In
addition, and perhaps of greater importance, the physician-researcher’s
obligation to adhere to the study protocol might well mean that alterations in
the care of the individual patient, from which he or she could potentially
benefit, might well not occur if doing so would violate the study protocol’s
strict requirements.92 Off-protocol, the alteration would be made. The point
here is that researchers
are not offering personalized medical therapy for individual patients. Rather,
they seek to answer clinically relevant scientific questions by conducting
experiments that test the safety and efficacy of treatments in groups of
patients. . . . Protocols governing [randomized controlled trials] frequently
restrict flexibility in dosing and use of concomitant medications. These
features of research design are implemented to promote scientific validity, not
93
to promote therapeutic benefit.

Some evidence both of confusion regarding the research enterprise and of
possible examples of therapeutic misconceptions can be found in accounts of
recently conducted empirical research.94 There also is some evidence that
disclosure of conflicts of interest may actually encourage potential subjects to
agree to participate in a study. In Dr. Grady’s study, for example, one of the
subjects observed that knowledge of a patent interest would be a positive factor
in encouraging the researcher to be accurate with study data: “that [consulting]
would make me think, oh, he’s really on board with this . . . it would be a
positive . . . [and] make me a little more [interested in participating].”95 One of
the other studies concluded that participants to whom financial interests were
disclosed, believed the researcher would “do a better job,” and would not “cut
corners or try to do it the easy way instead of doing it the way it should be
done.”96 Such financial disclosures were interpreted “as an indication of the
integrity of the study or researcher. . . . Implicit in many comments was the
notion that the researcher who discloses a financial interest will be more likely
to conduct the study in an ethical fashion.”97 One could well imagine potential
participants, in considering financial conflicts of interest, particularly equity
interests, going even further and concluding that the researcher must really
“[m]y primary reason that I participate is because of the drug;” and that “[i]f I am ill and he’s
got a drug that could help me, I don’t care about [the investigator’s financial interests]”
(emphasis added)).
92. See Appelbaum et al., supra note 83, at 21.
93. Franklin G. Miller & Howard Brody, What Makes Placebo-Controlled Trials
Unethical?, 2 AM. J. BIOETHICS 3, 4–5 (2002).
94. See generally Weinfurt et al., supra note 66; Weinfurt et al., supra note 51, at 860.
95. Grady et al., supra note 69, at 596 (alterations in original).
96. Weinfurt, supra note 66, at 903 (internal quotation marks omitted).
97. Id. at 903.
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believe in the efficacy of the test article if he or she owns stock in the company
that manufactures it.98 Another respondent in Dr. Grady’s study, for example,
commented on the possibility that, as a result of an investigator’s equity
investment, the investigator might be “afraid he’s going to lose [money], then I
think he will put his best foot forward to make this a good drug . . . to make
sure you have the right data on it,” thus making it more likely that the
participant would join the study.99
A first cousin to the concept of therapeutic misconception is the concept of
clinical equipoise. This generally means that “the various arms of a study not
only must be in a position of equipoise vis-à-vis one another, but that they also
be in a position of equipoise with respect to other interventions the subjects
could receive outside of the study.”100 Therefore, the 2008 revised version of
the Declaration of Helsinki states: “The benefits, risks, burdens and
effectiveness of a new intervention must be tested against those of the best
current proven intervention . . . .”101 Consequently, it could be argued that the
only time a placebo controlled trial, for example, is appropriate would be when
no effective treatment exists or when existing treatments are inadequate for the
patient.102
As noted, some data suggests that information about conflicts of interest
presented to potential research participants may increase the likelihood that
they will participate. However, the increased willingness to participate may
well be based on two factors, neither of which may necessarily be true.
The first is that the researcher’s financial interests suggest that the
researcher has a strong belief in the test article’s efficacy or greater efficacy
than other treatment approaches. But, the potential subjects are not likely to
understand that this concept of clinical equipoise, so critical to the conduct of

98. See Grady et al., supra note 69, at 594, 598; see also Hampson et al., supra note 52, at
2334, 2336 tbl.4 (reporting that the majority of patients believed it was acceptable for researchers
or the health center where the trial was being conducted to each “own stock in the drug company
whose drug is being used” (internal quotation marks omitted)).
99. Grady et al., supra note 69, at 595 tbl.3 (second alteration in original).
100. COLEMAN ET AL., supra note 17, § 6.02(B)(4), at 262.
101. World Med. Ass’n, Declaration of Helsinki: Ethical Principles for Medical Research
Involving Human Subjects ¶ 32, at 5 (adopted 1964) (2008) [hereinafter Declaration of Helsinki],
http://www.wma.net/e/policy/pdf/17c.pdf; COLEMAN ET AL., supra note 17, § 6.02(B)(4), at 262
(providing a similar discussion and analysis of the 2000 revisions to the Declaration of Helsinki).
102. See Declaration of Helsinki, supra note 101, ¶ 32, at 5 (“The use of placebo, or no
treatment, is acceptable in studies where no current proven intervention exists . . . .”); see also
Trudo Lemmens & Paul B. Miller, Avoiding a Jekyll-and-Hyde Approach to the Ethics of Clinical
Research and Practice, 2 AM. J. BIOETHICS 14 (2002) (discussing the ethical tension inherent in
the use of placebo controls when the clinical researcher is bound by conflicting moral
commitments—the researcher to research itself and the medical clinician to upholding the duty of
care).
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research, cuts precisely against any such notion.103 By its very definition, the
concept of clinical equipoise requires that the researcher believe that the test
article is, in fact, not more likely to be a better alternative.104
The second possibility that emerges from the fact that disclosure may
actually increase willingness to participate, may well be based on the potential
subject’s idea that the mere fact that the disclosure was made serves to
significantly increase his or her level of trust in the researcher. Yet, the
disclosure may well have been required of the researcher by third parties such
as conflict of interests committees or IRBs and over the strong objection of the
researcher.
Moreover, other psychological factors may well undermine the
effectiveness of disclosure as a remedy for problems caused by conflicts of
interest. A number of investigators conducted a study of the “perverse effects”
of disclosing conflicts of interest.105 The study design did not involve
healthcare.106 Instead, it required individuals, or “estimators,” to estimate the
value of coins in several jars and paid them according to the accuracy of their
estimates.107 Some information was provided to the estimators by “advisors,”
(who were also study participants), but the advisors were paid, depending on
the experimental condition, on the basis of either how accurate or how high
(relative to actual values) the estimators’ estimates were.108 Advisors carefully
examined the jars and wrote reports containing their suggestions of the value
of the jar in question, which were then shared with the estimators.109 In the
condition where both estimators and advisors would be paid based on the
estimator’s accuracy, this fact was prominently noted in the advisor’s report to
the estimators.110 In the other condition, where payment to advisors would be
based on how high the estimators’ estimate was, no such information regarding
the basis of payment was provided to the estimator in the advisor’s report.111
Before making an estimate, estimators could only briefly look at the jars,
which were placed some distance from where they sat.112
The analogy to conflicts of interest in a research protocol is apparent. The
estimators are the potential research participants, the advisors are the
investigators, and the information provided by advisors to estimators is akin to

103. See Lemmens & Miller, supra note 102, at 15–16.
104. Id.
105. Daylian M. Cain et al., The Dirt on Coming Clean: Perverse Effects of Disclosing
Conflicts of Interest, 34 J. LEGAL STUD. 1, 20 (2005).
106. Id. at 9.
107. Id.
108. Id. at 8.
109. Id. at 9.
110. Cain et al., supra note 105, at 10.
111. Id.
112. Id. at 9–10.
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that in a consent document or discussion between research participants and
investigators. Such information, of course, in the human research context,
would include information about conflicts of interest.
The results of the study indicated that there was a general tendency to
underestimate jar values when incentives were aligned (i.e., both would be
paid on the basis of the accuracy of the estimator’s report), but where the
advisor’s reward would be based on how high the estimator’s stated valuations
were, there was a clear tendency on the part of advisors to exaggerate jar
values.113 The authors concluded that “[a] superficial analysis of disclosure
helps to explain the popularity of this purported remedy for conflicts of
interest: all parties appear to benefit.”114 But, the “more complex analysis”
questions this conclusion, and it indicates that the providers of information
benefited the advisors but not the estimators, thereby challenging “the belief
that disclosure is a reliable and effective remedy for the problems caused by
conflicts of interest.”115
The authors suggest that disclosure can fail because “(1) disclosure gives
advisors strategic reason and moral license to further exaggerate their advice”
(for our purposes, be it in a consent document or in the one-on-one discussion
between the patient and the researcher regarding participation in the study),
and “(2) [disclosure] may not lead to sufficient discounting to counteract this
effect.”116 That is, people generally do not discount advice from biased
advisors as much as they should because disclosure may increase trust. This
might well occur when advisors’ (or researchers’) conflicts of interest are
disclosed.117 Moreover, disclosure can actually increase the bias in advice
because it “leads advisors to feel morally licensed and strategically encouraged
to exaggerate their advice even further. . . . [D]isclosure may fail to solve the
problems created by conflicts of interest and may sometimes even make
matters worse.”118 As one of the studies noted above suggests, for example,
knowledge of a researcher’s investment in a company sponsoring the study, or
the researcher’s affiliation as a consultant to the company, only serves to
promote confidence that the test article or drug is likely to improve the study
participant’s condition.119

113.
114.
115.
116.
117.
118.
119.

Id. at 12–14.
Id. at 18.
Cain et al., supra note 105, at 20.
Id. at 22.
Id. at 6.
Id. at 1, 22.
See supra text accompanying notes 93–99.
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III. RESEARCH SCANDALS
Several prominent research scandals involving conflicts of interest, a
number of which are particularly infamous, began to surface in 1998.120
Among the more notable situations are those described in Moore v. Regents of
the University of California,121 as well as the facts surrounding the story of the
death of Jesse Gelsinger in 1999,122 and the events at the Fred Hutchinson
Cancer Research Center in 2001.123 Newer ones, such as the PRODISC
clinical trial in 2008, are disclosed with some frequency.124
Recently, four of the largest manufacturers of artificial joints paid a total of
$310 million in penalties to settle federal accusations that they used fake
consulting agreements and other means to persuade surgeons to use their
products.125 Researchers at NIH accepted hundreds of thousands of dollars in
consulting fees, failing to inform agency officials, with “NIH doctors [seeing]
requirements to disclose outside consulting as ‘basically a bureaucratic
nuisance.’”126 Lately, there has been a spate of disclosures regarding
previously unidentified earnings by academic researchers from study sponsors.
Many of these came to light in response to congressional demands that the
sponsors produce lists of actual payments made. These responses indicated
significant payments to researchers who failed to report such payments to their
own institutional officials when they had been required to do so.127

120. See generally COLEMAN ET AL., supra note 17, § 2.01, at 57–61; Goldner, supra note 36,
at 379, 382, 389.
121. 793 P.2d 479 (Cal. 1990). In 1999, the California Supreme Court held that a treating
physician developing a cell line from the blood of a patient was required to tell the patient of the
physician’s personal interests that may affect his professional judgment. Id. at 484–85. The court
found that the physician’s failure to do so could render him liable for malpractice based on breach
of informed consent. Id.
122. See Goldner, supra note 36, at 379–80 (describing the death of an eighteen-year-old in a
gene therapy trial in which the lead scientist had a financial interest in a positive trial outcome).
123. Duff Wilson et al., Congress Takes on Medical-Trials Controversy, SEATTLE TIMES,
May 30, 2001, at A1 (reporting that 80 out of 82 subjects died in a clinical trial in which three
lead researchers and a Hutch-affiliated foundation held stock in a firm that held the commercial
rights to some of the drugs tested); see also COLEMAN ET AL., supra note 17, § 5.01, at 207, 225.
124. Reed Abelson, Financial Ties Cited as Issue in Spine Study, N.Y. TIMES, Jan. 30, 2008,
at A1 (noting doctors at approximately half of the seventeen research centers involved in the
study stood to profit financially if the device was successful).
125. Press Release, U.S. Dep’t of Justice, Five Companies in Hip and Knee Replacement
Industry Avoid Prosecution by Agreeing to Compliance Rules and Monitoring (Sept. 27, 2007),
available at http://www.usdoj.gov/usao/nj/press/files/pdffiles/hips0927.rel.pdf.
126. Rick Weiss, ‘Serious Misconduct’ by NIH Expert Found, WASH. POST, June 14, 2006, at
A6.
127. Gardiner Harris & Benedict Carey, Researchers Fail to Reveal Full Drug Pay, N.Y.
TIMES, June 8, 2008, at A1; see also Gardiner Harris, Top Psychiatrist Didn’t Report Drug
Makers’ Pay, Files Show, N.Y. TIMES, Oct. 4, 2008, at A1.
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The public has only recently learned that Dr. Charles B. Nemeroff, the
chairman of the psychiatry department at Emory University, apparently
violated both University rules and federal reporting regulations when he told
the institution’s administrators that he would earn under $10,000 in consulting
fees in 2004 from any single drug manufacturer.128 In fact, congressional
investigators learned that Nemeroff had already earned in excess of $98,000
from a sponsor at the time of the disclosure, and the sponsor paid him a total of
$170,000 that year.129 In both 2005 and 2006, Nemeroff also greatly exceeded
the federal regulations’ $10,000 threshold from any one source such that
reporting is required.130 From 2000 through 2006, Nemeroff earned $960,000
from one sponsor alone, but he declared less than $35,000 on his disclosure
forms.131 In fact, he earned a total of $2.8 million from sponsors between 2000
and 2007 and failed to disclose $1.2 million of it.132 In response, he claimed
that “to the best of my knowledge, I have followed the appropriate university
regulations concerning financial disclosures.”133
Between 2003 and 2006, Nemeroff was the principal investigator on a $3.9
million NIH study.134 Had Emory known about his higher income, the
University would have been required to inform NIH of his potential conflict or
remove him as principal investigator.135
The federal government froze funds for his then current $9.3 million
project and now requires more of Emory in the way of checks and
documentation on researchers’ outside activities and potential conflicts of
interest before awarding any additional funding.136 After the congressional
investigation became public, Nemeroff voluntarily resigned his department
chairmanship on a temporary basis.137
Internal Emory documents indicated that on a number of prior occasions
the University questioned Nemeroff’s outside activities and relationships with
drug companies.138 In 2004, for example, there was a similar investigation of
128. See Mike King, Time to Disinfect Research Dollars, ATLANTA J. CONST., Oct.12, 2008,
at A15.
129. See id.
130. Id.
131. Id.
132. Harris, supra note 127.
133. Gayle White & Craig Schneider, Psychiatrist as Divisive as He Is Gifted, ATLANTA J.
CONST., Oct. 12, 2008, at A1 (internal quotation marks omitted).
134. King, supra note 128.
135. Id.
136. See Harris, supra 127; see generally S. Van McCrary et al., A National Survey of
Policies on Disclosure of Conflicts of Interest in Biomedical Research, 343 NEW ENG. J. MED.
1621 (2000) (discussing models proposed by the Institute of Medicine for managing conflicts of
interest).
137. King, supra note 128.
138. White & Schneider, supra note 133.
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Nemeroff’s consulting relationships with outside companies.139
The
University’s conflict of interest committee identified multiple “serious” and
“significant” violations of University procedures that were intended to protect
patients.140 The New York Times concluded that “the university apparently
took little action against Dr. Nemeroff and made no effort to independently
audit his consulting income.”141 Moreover, the Times noted that in conjunction
with a 2000 investigation, Nemeroff wrote a letter to the University that
explicitly noted his membership on some dozen corporate advisory boards,
pointing out that one company donated an endowed chair and another was
likely to do so.142 The letter further observed that one funded a career
development award in the department and two others had been asked to do
so.143 Thus, part of the University administration’s lack of response could well
be that it had its own conflicts of interest and stood to gain mightily by these
kinds of corporate relationships. The entire attitude regarding these conflicts
could also be explained by an unusually minimalistic attitude of federal
agencies, research institutions, and professional organizations toward
regulating conflicts of interest in research.144
Two critical facts emerge from these examples. First, in some of these
instances research participants were injured, at least indirectly, but perhaps
directly, as a result of the intervention. Second, these scandals damaged public
support for the research enterprise.145
IV. EXISTING CONFLICT OF INTEREST REGULATIONS
Several empirical studies demonstrate clinical researchers’ lack of
knowledge of conflict of interest issues and guidelines,146 inaccurate reporting
of financial conflicts,147 and the very limited extent to which institutions

139. Harris, supra note 127.
140. Id.
141. Id.
142. Id.
143. Id.
144. Harris, supra note 127.
145. See, e.g., ADIL E. SHAMOO & DAVID B. RESNIK, RESPONSIBLE CONDUCT OF RESEARCH
192 (2009) (“[Conflicts of interest] not only can affect the integrity of the research process, but
also can undermine the public’s trust in the science by creating the perception that research is
biased, unreliable, or morally tainted.”); Catherine D. DeAngelis, Editorial, Conflict of Interest
and the Public Trust, 284 JAMA 2237 (2000); Richard R. Sharp & Mark Yarborough, Informed
Trust and the Financing of Biomedical Research, 34 J.L. MED. & ETHICS 460 (2006); Research
Scandals: Public Wants to Know Who’s Minding the Store?, MED. ETHICS ADVISOR, July 1999,
http://www.ahcpub.com/hot_topics/?htid=1&httid=1424.
146. Sharmon Sollitto et al., Intrinsic Conflicts of Interest in Clinical Research: A Need for
Disclosure, 13 KENNEDY INST. ETHICS J. 83 (2003).
147. Harris, supra note 127; Anthony Tweedale, Letter to the Editor, Accuracy of Declared
Conflicts of Interest, 114 ENVTL. HEALTH PERSP. 267, 267 (2004).
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engage in effective management of conflicts and practically never penalize
violations of disclosure requirements.148 As Senator Charles E. Grassley (RIowa), who has been leading the congressional inquiry into these unreported or
underreported conflicts of interest, commented, “[a]fter questioning about 20
doctors and research institutions, it looks like problems with transparency are
everywhere . . . . The current system for tracking financial relationships isn’t
working.”149 After reviewing the results of the congressional investigation, the
Times article concluded: “The findings suggest that universities are all but
incapable of policing their faculty’s conflicts of interest. Almost every major
medical school and medical society is now reassessing its relationships with
drug and device makers.”150 The existing world of regulation of conflicts of
interest in research is woefully inadequate.151
A.

Federal Regulations and Guidance

At the federal level,152 the only formal regulations adopted through the
notice-and-comment rulemaking process come from the Food and Drug
Administration (FDA)153 and the Public Health Service (PHS).154 There is a
reporting “policy” for the National Science Foundation (NSF) that was not
subject to the notice-and-comment rulemaking process.155 But the rules for
NSF are practically identical to those for the PHS. Federal regulations to
protect human subjects apply to research funded by the seventeen government
agencies that have adopted the “Common Rule,”156 and to research seeking
FDA approval of drugs, biological agents, or devices.157
Health and Human Services (HHS) regulations158 apply to research
involving human subjects conducted by HHS or to research that is funded in

148. See, e.g., Harris, supra note 127.
149. Id. (internal quotation marks omitted).
150. Id.
151. See generally Karen J. Maschke, Human Research Protections: Time for Regulatory
Reform?, HASTINGS CTR. REPORT, Mar.–Apr. 2008, at 19; Anna C. Mastroianni, Sustaining
Public Trust: Falling Short in the Protection of Human Research Participant, HASTINGS CENTER
REP., May–June 2008, at 8.
152. For a detailed discussion of federal regulations regarding financial conflicts of interest in
human subjects research, see Mark Barnes & Patrik S. Florencio, Investigator, IRB and
Institutional Financial Conflicts of Interest in Human-Subjects Research: Past, Present and
Future, 32 SETON HALL L. REV. 525, 531–39 (2002).
153. See Financial Disclosure by Clinical Investigators, 63 Fed. Reg. 5,233 (Feb. 2, 1998)
(codified at 21 C.F.R. § 54 (2008)).
154. See Objectivity in Research, 60 Fed. Reg. 35,810 (July 11, 1995) (codified as amended
at 42 C.F.R. § 50.601–.607 (2008)).
155. See Investigator Financial Disclosure Policy, 59 Fed. Reg. 33,308 (June 28, 1994).
156. See COLEMAN ET AL., supra note 17, § 3.02, 106–07.
157. See 21 C.F.R. § 50.1; COLEMAN ET AL., supra note 17, passim.
158. See Protection of Human Subjects, 45 C.F.R. § 46 (2008).
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whole or in part by HHS.159 But these regulations, as noted earlier, do not
address in any direct way the issue of conflicts of interest.160 FDA regulations
pertaining to human subjects research apply to research involving products
regulated by the FDA.161 One portion of the FDA regulations essentially
mirrors these HHS regulations, but again, the federal support is not necessary
for the FDA regulations to be applicable.162 When research involving products
regulated by the FDA is funded, supported, or conducted by the FDA and/or
HHS, both the HHS and FDA regulations apply.163
FDA regulations are relatively narrow in scope. They are directed at study
sponsors, such as pharmaceutical and device manufacturers, at the time that
there is a submission of clinical data to support claims of safety and
effectiveness of products that the agency regulates.164 The agency’s principal
concern is whether such financial relationships might jeopardize the reliability
of the data submitted.165 Specifically, what must be disclosed are “significant
payments of other sorts” from the sponsor of over $25,000 in payments beyond
the costs of the study while the study is being carried out and for one year
thereafter.166 In addition, the sponsor must disclose any significant equity
interests held by the investigator in the sponsor, which is defined as any equity
of a privately held entity or over $50,000 in a public company.167
Further, prior to an investigator becoming involved in a study, the sponsor
of a “covered clinical study”168 that is the basis of an Investigational New Drug
(IND) or Investigational Device Exemption application, must obtain financial
information before the study begins so as to possess the data that will be
required when applying to market the test article.169 There is no requirement
that the FDA, the sponsor of the study, or the institution where the study is
being conducted review the financial data, disclose the data to study

159.
160.
161.
162.

45 C.F.R. § 46.101(a).
See supra text accompanying notes 22–25.
21 C.F.R. §§ 50, 54, 56, 312, 812.
See JOHN D. MAHONEY, NAT’L INST. OF HEALTH, NIH INITIATIVE TO REDUCE
REGULATORY BURDEN: IDENTIFICATION OF ISSUES AND POTENTIAL SOLUTIONS § V (1999),
http://grants.nih.gov/grants/policy/regulatoryburden/humansubjectsprotection.htm;
see
also
sources cited supra note 159.
163. See 45 C.F.R. § 46.101(a); see also U.S. Food & Drug Admin., Frequently Asked
Questions: Protection of Human Subjects Research, http://www.fda.gov/oc/ohrt/IRBS/faqs.html
(last visited June 14, 2009) (follow “Frequently Asked Questions” hyperlink; then follow “IRB
Organization” hyperlink).
164. See 21 C.F.R. § 54.
165. Id. § 54.1; see also Financial Disclosure by Clinical Investigators 63 Fed. Reg. 5,233
(Feb. 2, 1998).
166. 21 C.F.R. § 54.2(f).
167. Id. § 54.2(b).
168. See id. § 54.2(e) (defining “covered clinical study” for the purposes of FDA regulation).
169. See id. §§ 312.53, 812.43.
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participants, or otherwise put in place a management plan while the study is
being conducted. The only possible implication of such financial conflicts of
interest is the remote possibility that the FDA might ultimately refuse to allow
the test device to be marketed, based on its conclusion that the data was
unreliable due to the conflicts.170
For the PHS, which includes NIH and the Small Business Innovation
Research Program, the arrangement is significantly different. To apply for a
grant the institution has to certify that it enforces a written institutional conflict
of interest policy.171 The policy must require that investigators disclose known
“Significant Financial Interests,” which would “reasonably appear to be
affected by the research,” to the institution’s “designated official.”172 The
designated official could be an individual or something like a conflict of
interest committee. Here, the term Significant Financial Interest means “salary
or other payments for services (e.g., consulting fees or honoraria); equity
interests (e.g., stocks, stock options or other ownership interests); and
intellectual property rights (e.g., patents, copyrights and royalties from such
rights),” in excess of $10,000 in value, more than a five percent ownership
interest in a single entity, or similar interests expected to exceed $10,000
during the next twelve-month period.173
The institution itself does not need to further disclose any details regarding
the conflict of interest, unless it is unable to “manage, reduce or eliminate” the
conflict.174 While the PHS agency does not define “manage, reduce or
eliminate,” the rules provide some examples of conditions or restrictions that
the institution may impose to do so.175 These include: “[p]ublic disclosure of
significant financial interests; [m]onitoring of the research by independent
reviewers; [m]odification of the research plan; [d]isqualification from
participation in all or a portion of the research funded by the [agency];
[d]ivestiture of significant financial interests; or [s]everance of relationships
that create actual or potential conflicts.”176 If an institution determines that the
investigator’s failure to comply with its conflicts of interest policy resulted in a
“biased design, conduct, or reporting of the PHS-funded research,” it is to
notify the awarding agency of “the corrective action taken or to be taken.”177
The agency will then “consider the situation and, as necessary, [either] take
appropriate action [itself], or refer the matter [back] to the Institution for
170. Id. § 54.1.
171. Institutional Responsibility Regarding Conflicting Interests of Investigators, 42 C.F.R.
§50.604 (2008).
172. Id.
173. Id. § 50.603.
174. Id. § 50.604.
175. Id. § 50.605.
176. 42 C.F.R. § 50.605.
177. Id. § 50.606(a).
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further action,” including directing the institution on “how to maintain
appropriate objectivity in the funded project.”178 The agency has a variety of
other remedies, including the suspension of funding.179 Still, there are no other
specific standards in place to guide institutional behavior.180 There are no
limitations, per se, on dollar amounts that may be received, or on the maximum
amount of percentage of equity interests that an investigator may hold. The
government simply delegates responsibility to the institution which, itself, may
have a conflict of interest in the research being conducted, or in maintaining
the goodwill of an employee who brings significant resources to the
institution.181 There is no requirement of disclosure to potential research
participants.
The Office of Human Research Protections (OHRP), the enforcement
agency for regulations regarding the treatment of human subjects, provides
investigators with a “guidance document” (notably not a regulation) which
raises “points to consider” regarding financial relationships.182 OHRP’s
“points to consider” include “suggesting” (1) the possible establishment of
conflict of interest committees, (2) the need for potential management of
conflicts of interest by the institution, and (3) the determination of whether
particular individuals should report financial interest to such a committee.183

178. Id.
179. Id. § 50.606(b).
180. In the spring of 2009, a letter was issued by the acting director of NIH in response to
an inquiry from congressman concerned with ensuring that stimulus money going to the
agency not be compromised by potential conflicts of interest. In it he indicated that NIH
was considering the issuance of a notice of proposed rulemaking regarding extramural
research conducted by the agency. Issues that would likely be addressed include (a) a
requirement that grantees provide details on financial conflicts and how they are managed;
(b) defining ‘significant financial interest;’ (c) requirements for the identification and
management of conflicts by institutions; (d) addressing the issue of assuring institutional
compliance; (e) requiring institutions to report additional information to the PHS; and (f)
addressing institutional conflicts of interest.
Forthcoming Proposed Rule on Conflicts to Include New Requirements, NIH Chief Says, 8 Med.
Res. L. & Pol’y Rep. 311 (May 6, 2009). Soon thereafter, however, NIH’s acting deputy director
for extramural research indicated that the agency’s review of NIH policies “might end in a few
months with a decision to leave regulations just as they are now.” Paul Basken, NIH Makes No
Promises As It Considers Regulations on Financial Conflict CHRON. HIGHER ED., May 14, 2009,
http://chronicle.com/daily/2009/05/18090n.htm?utm_source=at&utm_medium=en.
181. See 21 C.F.R. § 50.604 (2008).
182. Financial Relationships and Interests in Research Involving Human Subjects: Guidance
for Human Subject Protection, 69 Fed. Reg. 26,393–97 (May 12, 2004).
183. Id. at 26,396.
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Private Organization Policies

In February 2008, the Association of American Medical Colleges (AAMC)
and the Association of American Universities (AAU) together issued a helpful
report, directed at institutions, which advocated the adoption of more
consistent policies and practices in implementing comprehensive conflicts of
interest programs.184 Among the recommendations are ones to require the
broadening of the definition of “covered individual” beyond the principal
investigator, so as to include others who share responsibility for designing,
conducting, or reporting of funded research and to the spouses and dependent
children of each of these individuals.185 In addition, the report recommends
more carefully defining the “compelling circumstances” that would overcome
AAMC’s earlier policy recommendation that required a rebuttable presumption
against participation in research by conflicted investigators.186 The purpose of
enumerating compelling circumstances would be to define the stages of
research and the specific activities for which there are compelling reasons to
permit the conflicted researcher to be involved, and to structure and approve a
management plan that would clearly restrict the investigator in accordance
with a pre-determined policy.187
In addition, the report argues in favor of the notion that the reporting
requirement pertaining to outside financial interests related to professional
responsibilities should be extended to eliminate any de minimis threshold, even
if, for example, the PHS $10,000 line might still be used to define what is a
“Significant Financial Interest” that would trigger the rebuttable presumption
of non-participation.188 It also notes that institutions might want to exempt
certain kinds of income, such as well-defined types of consulting fees,
honoraria for academic activities, and the like.189 On the other hand, the report
recommends that institutions make clear that reporting is required for all
outside financial interests, directly or indirectly related to their professional
responsibilities, irrespective of whether the individual believes that such

184. AAMC-AAU ADVISORY COMM. ON FIN. CONFLICTS OF INTEREST IN HUMAN SUBJECTS
RESEARCH, PROTECTING PATIENTS, PRESERVING INTEGRITY, ADVANCING HEALTH:
ACCELERATING THE IMPLEMENTATION OF COI POLICIES IN HUMAN SUBJECTS RESEARCH (2008)
[hereinafter AAMC-AAU, PROTECTING PATIENTS], available at https://services.aamc.org/
Publications/showfile.cfm?file=version107.pdf&prd_id=220&prv_id=268&pdf_id=107A.
185. Id. at 5–6.
186. See id. at 6–7; AAMC TASK FORCE ON FINANCIAL CONFLICTS OF INTEREST IN
CLINICAL RESEARCH, PROTECTING SUBJECTS, PRESERVING TRUST, PROMOTING PROGRESS:
POLICY AND GUIDELINES FOR THE OVERSIGHT OF INDIVIDUAL FINANCIAL INTERESTS IN HUMAN
SUBJECTS RESEARCH 7 (2001) [hereinafter AAMC, POLICY AND GUIDELINES], available at
http://www.aamc.org/research/coi/firstreport.pdf.
187. AAMC-AAU, PROTECTING PATIENTS, supra note 184, at 6–7.
188. Id. at 7–9.
189. Id. at 8.
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interests might reasonably be affected by present or anticipated future
research.190 It specifically addresses instances involving pre-clinical research
and suggests the disclosures should indicate if the research linked to the
financial interest is “reasonably anticipated” either to be a component of a
submission for an IND or to progress to research involving human subjects
within the next twelve months.191 If so, the conflict of interest committee
should determine if management plan types of stipulations should be applied to
the pre-clinical stage of the research.192
The report also recommends broadening the scope of disclosure of
managed conflicts, both within and outside of the institution, so as to include
within the scope of the individuals or organizations with which the disclosure
is to be shared, among others: all researchers, students, and trainees working
on the project; editors of publications to which a manuscript is submitted; and
oral or written public communication of research results.193 It also makes
recommendations regarding institutional conflicts of interest and on the
implementation of conflicts of interest policies.194
Several other groups have promulgated other voluntary guidelines
regarding conflicts of interest in human subjects research.195 For the most part,
these guidelines have received less attention among academic institutions and
in literature.
C. Institutional Policies
Institutional conflict of interest policies are all over the board, as empirical
research has noted.196 They differ in the amount of a financial interest that
would constitute a Significant Financial Interest with 68% of the 101
institution cohorts in the study using the PHS standard of $10,000, 27% using a
lower dollar amount, and one using the $25,000 FDA limit.197 Sixty-one
190.
191.
192.
193.
194.
195.

Id. at 9.
Id.
AAMC-AAU, PROTECTING PATIENTS, supra note 184, at 9.
Id. at 9–10.
Id. at 13–35.
See PHARMACEUTICAL RESEARCH & MFRS. OF AM., PRINCIPLES ON CONDUCT OF
CLINICAL TRIALS AND COMMUNICATION OF CLINICAL TRIAL RESULTS 2 (2004), available at
http://www.phrma.org/files/Clinical%20Trials.pdf; INT’L COMM. OF MED. JOURNAL EDITORS,
UNIFORM REQUIREMENTS FOR MANUSCRIPTS SUBMITTED TO BIOMEDICAL JOURNALS: WRITING
AND EDITING FOR BIOMEDICAL PUBLICATION 4–5 (2008), http://www.icmje.org/icmje.pdf; Am.
Soc’y of Gene Therapy, Policy of the American Society of Gene Therapy Financial Conflict of
Interest in Clinical Research (adopted 2000), http://www.asgt.org/position_statements/conflict_
of_interest.php.
196. See SUSAN EHRINGHAUS & DAVID KORN, ASS’N OF AM. MED. COLLS., U.S. MEDICAL
SCHOOL POLICIES ON INDIVIDUAL FINANCIAL CONFLICTS OF INTEREST: RESULTS OF AN AAMC
SURVEY 3 (2004), available at http://www.aamc.org/research/coi/coiresults2003.pdf.
197. Id. at 4.
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percent include equity in companies that are not publicly traded regardless of
the percentage share of equity, and 64% include equity in such companies
regardless of estimations of value.198 Thirty-eight percent include royalty
income above a certain threshold, while 33% include it regardless of amount,
and 64% include non-royalty payments not directly related to reasonable costs
of research.199 Eighty-one percent allow a researcher with a Significant
Financial Interest to conduct human research in compelling circumstances.200
While 76% had established conflict of interest committees, merely 21% had
members from outside the institution serving on those committees.201
Institutions varied widely on how royalty rights would be shared, and there
was a variety of approaches used to review such agreements, specifically on
the issue of whether the researchers (and perhaps their institutions) might be
prohibited from being involved in future research on the technology that used
human subjects.202 In addition, the study indicated a broad range of
management techniques addressed in the policies.203
V. RESEARCHER PARADIGMS
Resistance to conflict of interest management plans generally stems from
the wide variety of attitudes held by researchers toward the entire issue of
conflicts of interest. Such resistance can range from what would appear to be
outright lying on conflict of interest reports to the institution, such as that
which appears in the case of Dr. Nemeroff from Emory discussed above,204 to
less troubling, yet nonetheless frustrating (at least to members of conflict of
interest committees), forms of resistance to the process and to proposed
management plans. One question that arises, but that may help provide some
guidance on how to go about remedying the situation, pertains to what
motivates researchers to take such an approach. My own experience on such a
committee, and discussions with committee members at various institutions,
has led me to develop a taxonomy of categories into which most researchers
fall: (1) The Ideologue, (2) The Wild-Eyed Scientist-as-Hero, (3) The
Entrepreneur, (4) The Naïve Careerist, and (5) The Legalist.
A.

The Ideologue

The Ideologue approaches conflicts of interest from laissez-faire economic
perspectives and espouses the view of non-intervention, particularly in

198.
199.
200.
201.
202.
203.
204.

Id.
Id.
Id.
EHRINGHAUS & KORN, supra note 196, at 3.
Id.
Id.
See supra text accompanying notes 127–33.
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commercial ventures, by the government, by the institution, or by both. The
Ideologue favors self-interest, competition, and natural consumer (i.e., research
participants’) preferences as forces leading to optimal prosperity and freedom.
She possesses a firm belief that the natural economic order, untouched by
regulations or adjustments, was designed to produce maximum well-being for
all. The Ideologue’s emphasis stems from the profit motive and from an
unyielding resolve that individual initiative, and only that, will make for
economic progress. Perhaps, as a scientist, the Ideologue might be forced to
concede the need for minimal regulation, but only if hard, irrefutable,
empirical data establishes that such regulation is needed—maybe not even
then!
B.

The Entrepreneur

The Entrepreneur focuses on initiating, or perhaps partially financing (if he
is able) new commercial enterprises, in large part to increase his own assets or
perhaps those of members of his family. He generally believes that he has a
right to act in an unrestrained fashion and may be adept at developing facile
arguments that enable him to avoid or even evade generally applicable rules.
He differs from the Ideologue in that there are no serious philosophical
premises to his position.
C. The Wild-Eyed Scientist-as-Hero
The Wild-Eyed Scientist-as-Hero believes that if left unfettered he will
cure diabetes, cancer, etc. His view is that no kind of interference (i.e.,
regulations) can appropriately be placed in his path. The end really does
justify the means.
D. The Naïve Careerist
The Naïve Careerist’s behavior is such that she single-mindedly fights
regulatory efforts on a number of grounds. She perceives herself as an
extremely ethical individual. She takes umbrage at any thought that she would
ruin her reputation as a competent, ethical researcher and clinician by having
what others perceive to be conflicts of interest that either (1) adversely affect
her patients who participate in research, or (2) that would lead her to
manipulate research data to positively influence the research outcome. Often
the nature of the conflict is such that she can readily align her own pecuniary
interest with that of her employer. Consequently, she can also justify resisting
the effort to deal with a conflict of interest on the basis that it will positively
influence not only her own bottom line but also that of the institution. She just
wants to be a good citizen. If in an academic setting, she may perceive her SFI
as helping to make up for financial sacrifices that she has made in choosing to
enter academia.
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The Legalist

This type of researcher is readily willing to follow the rules once he is
made aware of them. The vast majority of researchers who have conflicts of
interest fall under this category. They want to know what is required of them,
and they generally respond properly without issue.
VI. MANAGING CONFLICTS OF INTEREST
Most discussions of conflict of interest management begin with compelled
disclosure to at least the institution where the research is being conducted
and/or where the researcher has his or her principal ties.205 What kinds of
conflicts and the amounts below which disclosures need not be made varies on
a case-by-case basis.206 Other management strategies include, but are not
limited to, divestiture of part or all of equity interests, modification of research
plans, prohibition of participation in all or certain aspects of the research, and
limitations or prohibitions of activities not involving equity interests. Nonequity interest limitations could include consulting or engaging in certain
educational activities of the research sponsoring entity and/or not serving in
certain positions within the sponsoring entity. Similarly, where the researcher
has administrative responsibilities within the institution, such as chairing a
department or division, limits may be placed on his or her activities in those
capacities. Thus for example, the researcher might be prohibited from or
limited in passing upon applications for promotion and tenure or annual
evaluations, where individuals under the researcher’s supervision, be they
faculty members, staff, or students, might also be engaged in the research.
Where the conflict involves issues such as the physical location where the
research is being conducted (for example, using institutional space or
equipment for a “start-up” entity),207 a plan that includes fair market rental
payments to the institution by the researcher or the entity in which he or she
holds an equity interest may be required. In addition, where such start-up
entities are involved, it may well be necessary to develop a timetable for
moving the research outside the institution.
Even in the absence of a specific federal mandate, most research
institutions have established and maintain conflict of interest committees that
identify and attempt to manage conflicts of interest.208 Often committee
members will assist researchers in negotiating the terms of such a management
plan. Several studies suggest, however, that the lack of uniform conflict of
205. See Barnes & Florencio, supra note 152, at 544.
206. Id.
207. See id. at 526.
208. PHS and NSF require that research institutions “report the existence of conflicts of
interest to the funding agency but allow the institutions to manage conflicts internally. The
regulations do not specify how to do so.” McCrary et al., supra note 136, at 1621, 1624–25.
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interest policies and the lack of clarity in those that do exist, allow many
financial conflicts of interest to go undetected and unmanaged, or inadequately
managed.209 Another study reports that the manner in which an institution
actually manages conflicts of interest in research often is not consistent with its
written policies.210
In January 2008, the Office of the Inspector General of the Department of
Health and Human Services issued in a report titled “National Institutes of
Health: Conflicts of Interest in Extramural Research.”211 The report, based
upon empirical data collected by the HHS-OIG, highlighted several areas
where it believes that the NIH’s oversight of grantee institutions’ financial
conflicts of interest is insufficient. Specifically, the OIG noted that “NIH
could not provide an accurate count of financial conflict-of-interest reports,”212
that “NIH is not aware of the types of financial conflicts of interest that exist
within grantee institutions,”213 and that “[m]any NIH Institutes’ primary
method of oversight is reliance on grantee institutions’ assurances that
financial conflicts-of-interest regulations are followed.”214

209. See id.; see also Elizabeth A. Boyd et al., Implementation of Financial Disclosure
Policies to Manage Conflicts of Interest, 23 HEALTH AFF. 206, 213 (2004) (“In the absence of a
clear and consistent definition of conflict of interest, individual committees have developed their
own sets of standards in evaluating financial disclosures. Those standards appear to be based on
specific institutional values that the committees felt were important to protect.”); Mildred K. Cho
et al., Policies on Faculty Conflicts of Interest at US Universities, 284 JAMA 2203, 2208 (2000)
(“Most policies on conflict of interest at major US research institutions lack specificity about the
kinds of relationships with industry that are permitted or prohibited.”); Elizabeth A. Boyd & Lisa
A. Bero, Improving the Use of Research Evidence in Guideline Development: 4 Managing
Conflicts of Interest, 4 HEALTH RES. POL’Y & SYS. 16 (2006), http://www.health-policysystems.com/content/4/1/16 (“We recommend the development of specific, detailed, structured
forms that solicit as much information as possible about the nature and extent of the competing
interests.”).
210. Recent empirical studies have not addressed this issue directly. For the most current
discussion of the topic, see Michaela A. Dinan et. al., Comparison of Conflict of Interest Policies
and Reported Practices in Academic Medical Centers in the United States, 13 ACCOUNTABILITY
RES. 325, 338, finding that in a study of 123 U.S. academic medical institutions with internal
IRBs, “in the absence of explicit language in formal policies, oversight officials did not always
agree about the actual practices of the institution.”
211. DEP’T HEALTH AND HUMAN SERVS., OFFICE OF INSPECTOR GEN., NATIONAL
INSTITUTES OF HEALTH: CONFLICTS OF INTEREST IN EXTRAMURAL RESEARCH (2008)
[hereinafter OIG, NIH: CONFLICTS OF INTEREST], available at http://www.oig.hhs.gov/oei/
reports/oei-03-06-00460.pdf.
212. Id. at 9.
213. Id. at 11.
214. Id. at 13.
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Although under the applicable federal regulations some investigators must
report financial conflicts of interest, this information is self-reported.215 In
particular, the OIG reported that because conflict of interest reports are not
required to detail the nature of the conflict, NIH is not aware of the types of
conflicts of interest that exist in grantee institutions.216 Further, “[t]he majority
of the Institutes do not have any proactive methods to ensure that grantees have
financial conflict-of-interest policies,” and as a result the Institutes must rely
solely on assertions by grantee institutions that they are properly managing
financial conflicts of interests that exist in their research endeavors.217 The
OIG also found that systems tracking financial conflicts of interest are
inadequate or do not exist at all, making it virtually impossible for the
Institutes to follow up on identified conflicts of interest.218
Based upon these insufficiencies the OIG recommended that the NIH
“increase oversight of grantee institutions to ensure their compliance with
federal financial conflict-of-interest regulations,” that it “require grantee
institutions to provide details regarding the nature of financial conflicts of
interest and how they are managed, reduced, or eliminated”, and that it
“require institutes to forward to [the Office of Extramural Research (OER)] all
financial conflict-of-interest reports that they receive from grantee institutions
and ensure that OER’s conflict of interest database contains information on all
conflict-of-interest reports provided by grantee institutions.”219
In 2009 the OIG of HHS issued another report, entitled “The Food and
Drug Administration’s Oversight of Clinical Investigators’ Financial
Information.”220 The purpose of the this report was “[t]o describe the extent
and nature of clinical investigators’ disclosed financial interests reported to the
Food and Drug Administration (FDA) for marketing applications approved in
fiscal year (FY) 2007,” and “[t]o assess FDA’s oversight of clinical
investigators’ financial information.”221 The report does not assess problems
involving individual researchers or institutional failures in the area of conflicts
of interest, but rather those of the FDA itself in tracking potential conflicts
with respect to applications by sponsors for authority to market test articles.

215. Nat’l Inst. of Allergy & Infectious Diseases, NIH, Financial Conflicts of Interest for
Awardee: Standard Operating Procedure, http://www.niaid.nih.gov/ncn/sop/fcoi.htm (last visited
July 30, 2009).
216. OIG, NIH: CONFLICTS OF INTEREST, supra note 211, at 11.
217. Id. at 13.
218. Id. at 11.
219. Id. at 16–17.
220. See DEP’T OF HEALTH & HUMAN SERVS., OFFICE OF INSPECTOR GEN., THE FOOD AND
DRUG ADMINISTRATION’S OVERSIGHT OF CLINICAL INVESTIGATORS’ FINANCIAL INFORMATION
(2009) [hereinafter OIG, FDA REPORT], available at http://oig.hhs.gov/oei/reports/oei-05-07-00
730.pdf.
221. Id. at i.
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The report, nonetheless, is quite instructive for present purposes regarding the
need for an expanded role for both the federal government and for institutions
in regulating conflicts. The report points to inconsistency and a lack of
uniformity of process as underlying reasons why (a) 42% of marketing
applications had missing financial information, (b) no documentation of review
of financial interests existed for 31% of marketing applications, and (c) “[i]n
20 [%] of marketing applications, FDA reviewers did not take action and
sponsors did not indicate that they minimized potential bias during the clinical
trials.”222 The OIG found that “FDA cannot determine whether sponsors have
submitted financial information for all clinical investigators because FDA does
not have a complete list of clinical investigators,” nor does the agency use onsite inspections to confirm that the financial information submitted in the study
is complete.223 This certainly indicates that serious concerns about conflicts of
interest exist regarding procedures in the government agency whose mission is
to protect the public from drugs and devices, the testing of which needs to be
beyond reproach.
The OIG recommended that the FDA take a more active role to ensure that
“sponsors submit complete financial information for all clinical
investigators.”224 Specifically, the OIG suggested that the FDA include a
requirement that sponsors submit researchers’ financial conflict of interest
information as part of the agency’s already existing pre-trial application
process.225 The report noted that if the FDA “received financial information
before clinical trials, [it] could ensure that sponsors are collecting financial
information before trials and are taking action to ensure that disclosed financial
interests do not threaten human subjects or compromise data integrity.”226 To
achieve similar goals at an institutional level, new federal regulations are
needed that would vest conflict of interest committees with the ability to be
more active in conflict of interest management. One possible approach would
be to require that such a committee approve the conflict of interest
management plan for a research protocol before the protocol is even sent to an
IRB.227

222. Id. at ii.
223. Id. at ii, 15.
224. Id. at 23.
225. OIG, FDA REPORT, supra note 220, at 25.
226. Id.
227. Similarly, IRBs should have “look back” authority to review the findings and decisions
of the conflict of interest committee. See id. at 3. Presumably, for example, if an IRB is not
satisfied with a particular management plan, it should have the authority to refuse to approve the
research. It could require additional management techniques should it determine that, given the
nature of a particular protocol, the plan worked out by the conflict of interest committee and the
investigator insufficiently protected the rights of research participants. This might, on very rare
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In response to the significant public attention being paid to conflicts of
interest concerns over the past few years, as noted above, a variety of “trade
associations” have developed suggested voluntary guidelines for regulating
conflicts of interest.228 Apart from the various substantive inadequacies
presented by these proposals, a key difficulty simply is that they are
“voluntary,” with no or very limited enforcement mechanisms. 229 Thus, would
a pharmaceutical company be drummed out of the Pharmaceutical Researcher
and Manufacturers of America (PhRMA) should it fail to adopt or enforce a
suggested restriction?
Likewise, would a university be banned from
membership in the AAMC or AAU or from participation in those associations’
activities for similar failures? At least one relatively small “trade association,”
the North American Spine Society (NASS), has developed disclosure
requirements with a bit more teeth, but only in connection with participation in
the Society’s activities, and without addressing other potential management
techniques.230
As an historical matter, disclosure has been the primary and sometimes
sole vehicle used to manage conflicts of interest. The resolution of dilemmas
regarding disclosure also continues to plague those who write about the issue
in the context of publication requirements.231 Some of the very same questions
arise in connection with disclosure of conflicts of interest to conflict of interest
committees and to potential research subjects. Ongoing concerns include when
disclosures should be made, what level of financial interest should be
disclosed, what period of time should be covered by the disclosure, who should
the disclosure cover, and once the conflict is identified, how it should be
managed?

occasions, necessitate holding a joint meeting of the two committees to arrive at a consensus
approach.
228. See supra text accompanying note 195.
229. See, e.g., AAMC-AAU, PROTECTING PATIENTS, supra note 184, at 4 (describing the
contents of the report as “guidance” and “recommendations” for member institutions to adopt);
PHARMACEUTICAL RESEARCH & MFRS. OF AM., CODE ON INTERACTIONS WITH HEALTHCARE
PROFESSIONALS 3 (2008) [hereinafter PHRMA CODE] (introducing its “updated and enhanced
voluntary Code on relationships with U.S. healthcare professionals”).
230. “This disclosure policy applies to all participants in all NASS activities, including those
who serve in committee and leadership positions within the society, speakers, and authors on
NASS publications, including but not limited to The Spine Journal (TSJ), SpineLine,
Contemporary Concepts and Clinical Guidelines.” N. Am. Spine Soc’y, NASS Disclosure Policy,
http://www.spine.org/Pages/PracticePolicy/EthicsProfConduct/NASSDisclosurePolicy.aspx (last
visited July 30, 2009). Sanctions for violations under the policy included, but are not limited to,
“one- or two-year suspensions of membership, membership expulsion, public letters of censure,
and/or—in conjunction with the Education Council Chairs—barring the member from presenting
at a specified number of future meetings.” Id.; see also Thomas M. Burton, Spine Doctors Are
Adopting Strict Rules on Payments, WALL ST. J., Jan. 24, 2009, at A3.
231. See generally Boyd & Bero, supra note 209.
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More significant is the fact that such disclosure requirements are now
clearly insufficient even if the questions just raised have been sufficiently
answered. As discussed earlier, disclosing conflicts of interest does not
adequately prevent improper physician behavior that can result from a variety
of sponsor inducements.232 Before describing a necessary, though many will
view it as painful, solution to the conflict of interest dilemma, consider the
following tale.
For nearly eighteen years I was a member of an IRB that, at that time,
reviewed biomedical, behavioral, and social science research conducted at a
large university with an academic medical center.
During the final
approximately five years (1998 through December 2003) I served as the IRB’s
chair, resigning that position to assume a visiting professorship opportunity in
another part of the country. Nearly at the end of my tenure, I put together a
small, and what I thought to be adequately diverse and representative,
subcommittee of the IRB to review the possibility of having it collect
information and make judgments about researchers’ conflicts (albeit three
years after I had written an article arguing that this was necessary233). No such
review activity on research protocols of any kind was occurring at the
University at that time. I thought this subcommittee arrived at a relatively
benign proposal, which largely involved requiring certain minimum
disclosures with the possibility of some restrictions on researchers who held
substantial equity interests in entities for which they were doing research. The
proposal was largely based on the earlier issued AAMC report, discussed
above.234 When the proposal came before the full IRB, it was hit by a large
chorus of dissenters who ultimately carried the day. The proposal did not fail
because of concerns that the IRB already was overburdened. Rather, it failed
because of the concern that making our own institutional policies go anywhere
beyond merely requiring disclosure (either to the IRB or to potential research
participants), such that a management plan for a conflict or a prohibition on a
researcher conducting a study might result, would cause researchers to leave
the institution in droves. In other words, the fear that won the day was that top
researchers would simply go elsewhere, where conflict of interest policies
either did not exist or were far less “intrusive.” The majority of the IRB
membership took the position that any such interference with researchers’
abilities to conduct their research was unnecessary and unwarranted.
Consequently, in essence, the IRB should not adopt any policy that would
require investigators to go beyond the most minimal policy (if any) existing at
other academic health centers.

232. See discussion supra Part II.A–B.
233. Goldner, supra note 36, at 381–84.
234. AAMC, POLICY AND GUIDELINES, supra note 186.
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The problem is that this “race to the bottom”235 can be stopped only by the
government imposing the obligation to effectively deal with conflicts on the
institutions. What is needed is a uniform set of regulations—yes, a command
and control approach, albeit administered locally. This is critically necessary
to minimize conflict of interest scandals and to restore public confidence in
research.
VII. A PROPOSAL FOR REFORM
Are attempts to reform how financial conflicts of interests in human
subjects research are managed doomed to be a Sisyphean struggle? Certainly
not if an abolitionist position is adopted for financial conflicts of interest, and
such a policy is enforced with vigor and with meaningful and appropriately
severe sanctions for serious violations that would have a significant deterrence
effect.236 Despite all of the increased attention to such conflicts, as I argued
some nine years ago,237 I continue to believe that abolition, absent a clear
federal requirement, is unlikely. Moreover, such a federally mandated
abolition flies directly in the face of more than twenty-five years of other clear
federal policies, such as the entire scheme envisioned by the Bayh-Dole Act,
designed to foster the very kind of research that often gives rise to such
potential conflicts.238 Consequently, the likelihood of a federally imposed ban

235. Cf. Marcia Angell, Former Editor of THE NEW ENG. J. MED., Address at the NIH
Conference on Human Subject Protection and Financial Conflicts of Interest (Aug. 16, 2000)
(transcript available at http://hhs.gov/ohrp/coi/8-16.htm) (“[I]nstitutions need to [work together]
on this issue [of financial conflicts of interest] and develop a common policy. As it now stands,
investigators may threaten to leave institutions with stringent policies and go to more lenient
ones. That race to the bottom can be stopped only by the major academic medical centers joining
together to do the right thing.”).
236. Institutions rarely prohibit financial conflicts of interest outright. For example, a 2000
study analyzing the conflict of interest policies of the ten U.S. medical schools receiving the
largest amount of research funding from NIH found that one university “prohibited faculty from
having any financial interests, including stock options, consulting agreements, and decisionmaking positions that involved a company sponsoring the study,” that another university
“prohibited faculty and research staff from trading in stock or stock options in a company
sponsoring the research or selling the product or device being investigated,” but that policies at
the other universities in the study generally “stopped short of prohibitions.” Bernard Lo et al.,
Conflict of Interest Policies for Investigators in Clinical Trials, 343 NEW ENG. J. MED. 1616,
1618 (2000). While in the intervening time, given the increased attention to conflict of interest
issues, many institutions have placed some kinds of limitations on conflicts, there appear to be no
recent reports of institutions imposing a total ban on them for its researchers, nor have leading
professional organizations called for such a ban. See generally AAMC-AAU, PROTECTING
PATIENTS, supra note 184; INST. OF MED., CONFLICT OF INTEREST IN MEDICAL RESEARCH,
EDUCATION, AND PRACTICE (2009).
237. Goldner, supra note 36.
238. 35 U.S.C. §§ 200–212 (2006); see COLEMAN ET AL., supra note 17, § 2.02(c)(1), at 67–
69; supra text accompanying notes 28–31.
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appears to be nil. Still, if the research community and the government alike
are serious about addressing financial conflicts of interest in research, a
fundamental change in the way conflicts of interest are viewed and ultimately
managed will be required.
Thus, I have concluded that the appropriate response to concerns about
conflicts of interest is to develop new federal conflict of interest regulations
promulgated through administrative law procedures that involve notice and
comment.239 The principal advantage of such a new federal regulatory regime
is that it could be constructed so as to be practically universal in its
applicability, thus overcoming concerns about the “race to the bottom,” which,
no doubt, still exists. To ease implementation, many of the new regulations
could be modeled after existing IRB regulations under which institutions have
worked for many years.
New federal conflict of interest committee regulations should require that
institutions develop, through an assurance process similar to that established
for IRBs,240 conflict of interest committees that meet certain membership
criteria, again similar to those applicable for such boards and including nonaffiliated members. Federal regulations require that each IRB have “at least
five members with varying backgrounds to promote complete and adequate
review of research activities commonly conducted by the institution.”241 The
regulations further require that each IRB include “at least one member who is
not otherwise affiliated with the institution.”242 In its February 2008 report,
AAMC-AAU recommended that an institution’s conflict of interest committee

239. A movement for uniform national conflict of interest rules is gaining strength. See, e.g.,
Ted Agres, FASEB: Nationalize Conflict Rules, THE SCIENTIST, July 17, 2007, www.thescientist.com/news/display/53381/ (on file with Saint Louis University Law Journal).
240. For example, 45 C.F.R. § 46.103(a) (2008), states: “Each institution engaged in research
which is covered by this policy and which is conducted or supported by a federal department or
agency shall provide written assurances satisfactory to the department or agency head that it will
comply with the requirements set forth in this policy.” (emphasis added). In an earlier article, I
argued for IRB review of conflicts of interest. See Goldner, supra note 36. In the intervening
years, however, I have become convinced that (a) IRBs already have too much on their plates and
typically are both understaffed and overworked, and that (b) the level and type of expertise
required to engage in appropriate regulation of financial conflicts of interest is such that, except at
institutions engaging in a minimal level of research, it would be wiser to establish a separate body
that focuses on conflicts of interest alone. Also, if the research site is not affiliated with an
institution having such a committee, the site would have to find a duly established conflict of
interest committee to review and manage any conflicts that are identified. Finally, any conflict of
interest committee that is established under such an assurance must have the authority, similar to
that vested in existing IRBs, see 45 C.F.R. § 46, to delay the initiation of research until the
committee’s concerns are adequately addressed, and irrespective of the desire of institutional
officials given the potential for institutional conflicts of interest.
241. 45 C.F.R. § 46.107(a).
242. Id. § 46.107(d).
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be composed of at least seven members, “of whom at least two [are] members
of the public with no active transactional relationships with the institution.”243
Additionally, AAMC-AAU recommended that “[o]ne of the public members
should have no institutional affiliation at all.”244 The purpose of a conflict of
interest committee is to provide an ethical analysis of the effect of a conflict on
research and the appropriate way to remedy it when necessary. A majority of
members without institutional ties would be preferable.245 This is something
that intelligent lay members of a conflict of interest committee would be
qualified to do.
The new regulations should also establish requirements for disclosure of
all financial conflicts of interest of any amount to the conflict of interest
committee,246 provide a non-exclusive list of potential management techniques,
grant the conflict of interest committee the authority to prohibit research from
commencing or continuing until conflict of interest concerns are resolved,247
and require that serious or continuing violations are reported to appropriate

243. AAMC-AAU, PROTECTING PATIENTS, supra note 184, at 39.
244. Id.
245. In Denmark, for example, it is required by law that there always be one more lay
member than professional member on IRB or Research Ethical Committees. Søren Holm, How
Many Lay Members Can You Have in Your IRB?—An Overview of the Danish System, 14 IRB 8
(Nov.–Dec. 1992). A majority of members without institutional ties would be preferable since
the conflict of interest committee should, ideally, be divorced from institutional politics. Holm
notes that “[o]utside observers at committee meetings have found that the most valuable
contributions are often made by lay members, who often seem better able to spot . . . an
inappropriate trade off between risks and benefits.” Id; see also Goldner, supra note 17, at 63,
107.
246. As noted earlier, PHS and NSF require that research institutions report the existence of
financial conflicts of interest over certain thresholds to the funding agency but allow these
conflicts to be managed internally. See supra note 208. As recommended by the AAMC-AAU,
financial conflicts of interest of any amount should be reported to the institution, and the PHS de
minimis thresholds should continue to guide disclosure to the appropriate non-institutional
entities. See AAMC-AAU, PROTECTING PATIENTS, supra note 184, at 8 (“The requirement for
reporting a covered individual’s outside financial interests that are directly or indirectly related to
professional responsibilities to the institution should be extended to eliminate any de minimis
threshold. . . . However, the PHS de minimis thresholds may continue to be used to define
significant financial interest for the purpose of applying the rebuttable presumption against
participation by a conflicted investigator in human subjects research.”).
247. Under 45 C.F.R. § 46.113, IRBs have “the authority to suspend or terminate approval of
research that is not being conducted in accordance with the IRB’s requirements or that has been
associated with unexpected serious harm to subjects.” Conflict of interest committees should
have the same power to suspend or terminate approval of research where, for example, a
researcher is non-compliant with a conflict of interest management plan, or where a conflict is so
egregious as to appear to cause serious harm to the research.
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governmental agencies.248 Violations of such regulations, that is the failure of
an institution to deal with conflict of interest concerns appropriately and in
accordance with the federal guidelines, should result in suspension of federal
funding of research for some or all projects at the institution.249 Conflict of
interest committees should be federally mandated to review and approve
research proposals prior to submission to external funding agencies or, if no
external funds are involved, then certainly prior to commencement of research.
Similarly, researchers who fail to report conflicts or who otherwise violate
conflict of interest regulations should be subject to a range of sanctions,
including limitations on participation in research projects, debarment from
receiving federal funding, and other penalties.250
New federal regulations should also require public disclosure of
investigator conflicts of interest, both on the NIH-sponsored internet site,
www.clinicaltrials.gov,251 and in informed consent documents provided to
participants. In particular, such a requirement should apply where the conflict
involves equity interests252 or in other situations where the conflict of interest
committee determines disclosure to be appropriate.
Institutions should be required to mandate training of all investigators in
both the ethical norms that underlie appropriate conflict of interest reporting
and management prior to the submission of any research protocols for
institutional approval. Such educational efforts should include instruction in
the proper completion of reporting documents.
To make clear why potential research participants should carefully
consider the effects of such conflicts of interests on their willingness to
participate, conflict of interest committees should have the power to require
descriptions of particular conflicts in the portion of the consent document
regarding risks of participation; albeit set out in a separate paragraph from
other types of risks. This would be in accord with the IRB regulations that
require informed consent documents to include “[a] description of any

248. Id. (“Any suspension or termination of approval shall include a statement of the reasons
for the IRB’s action and shall be reported promptly to the investigator, appropriate institutional
officials, and the Department or Agency head.”).
249. Cf. 45 C.F.R. § 46.123.
250. Similar to AAMC-AAU’s recommendations, a presumption of the need for disclosure
should exist. For an analogous discussion of sanctions for scientific misconduct, see Goldner,
supra note 36, at 298–307. See also supra text accompanying notes 129–41.
251. Food and Drug Administration Amendments Act of 2007, Pub. L. No. 110-85, § 810,
121 Stat. 823, 904–22 (to be codified at 42 U.S.C. § 282) (requiring that a “responsible party,” for
example the sponsor or principal investigator, register and report results of certain “applicable
clinical trials”); see Protocol Registration System (PRS) and U.S. Public Law 110-85,
ClinicalTrials.gov, http://prsinfo.clinicaltrials.gov/fdaaa.html (last visited July 30, 2009).
252. See supra text accompanying notes 48–99 (discussing potential research participants’
particular concerns about researchers’ equity interests versus other types of conflicts).
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reasonably foreseeable risks or discomforts to the subject.”253 Certainly,
conflicts of interest have caused a variety of serious problems to research
subjects; problems that could be characterized as risks or causing
discomfort.254
Beyond the baseline federal regulations suggested, research institutions
should retain the power to develop additional policies that may limit or
prohibit conflicts of interest so that standards remain “based on specific
institutional values that the committees [feel are] important to protect.”255
Existing federal IRB regulations provide a valuable framework for
restructuring and improving the current conflict of interest committee scheme.
While few would argue that the IRB regime has been entirely successful, it is
important to recognize that the perfect is the enemy of the good.
CONCLUSION
Financial conflicts of interest are no longer research’s dirty little secret.
Widespread publicity and several notable research scandals, among other
factors, have brought this issue to the forefront of discussions of regulatory and
legislative reform. In fact, financial conflicts of interest have been tabbed the
most important issue for medical research in 2009.256 Senator Grassley and
other lawmakers are actively investigating a variety of individual and
institutional conflicts of interest in research.257 It would not be surprising if, in
the near future, prosecutions were brought. The NIH is in the process of
revising its external conflict of interest policy and regulations.258 In January
2009, the OIG concluded that “[f]inancial relationships between researchers

253. 45 C.F.R. § 46.116(a)(2).
254. See discussion supra Part III; see also Goldner, supra note 237.
255. Boyd & Bero, supra note 209, at 2213.
256. Conflict of Interest Said Top Issue in 2009, 8 Med. Res. L. & Pol’y Rep. 5 (BNA) (Jan.
7, 2009).
257. Press Release, U.S. Senate Comm. on Fin., Grassley Calls on Congress and NIH Leaders
to Identify Conflicts of Interest in Taxpayer Sponsored Medical Research (June 25, 2008),
http://finance.senate.gov/press/Gpress/2008/prg062508CEG%20urges%20NIH.pdf; Press
Release, IowaPolitics.com, U.S. Sen. Grassley: Grassley, Kohl Continue Campaign to Disclose
Financial Ties Between Doctors and Drug and Device Companies (Jan. 22, 2009),
http://www.iowapolitics.com/index.iml?Article=146479; see also John Fauber, Doctors Face
Pressure to Disclose All Side Pay, JSONLINE (Wis.), Jan. 11, 2009, http://www.jsonline.com/
features/health/37397284.html; Andis Robeznieks, Curbs Put on Mass. General Researcher’s
Activities, MODERNHEALTHCARE.COM, Dec. 31, 2008, http://www.modernhealthcare.com/article/
20081231/REG/312319975 (on file with Saint Louis University Law Journal); David Wahlberg,
UW Hospital Surgeon Properly Received Millions from Medical Company, WIS. ST. J., Jan. 16,
2009, http://www.madison.com/wsj/topstories/433229.
258. Conflict of Interest Said Top Issue in 2009, supra note 256.
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and medical companies may compromise the safety of human subjects and the
integrity of research data.”259 The time is ripe for regulatory reform.

259. OIG, FDA REPORT, supra note 220, at 1; see Conflict of Interest Said Top Issue in 2009,
supra note 256.
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